Skip to main content
The Cochrane Database of Systematic Reviews logoLink to The Cochrane Database of Systematic Reviews
. 2025 Jul 14;2025(7):CD013166. doi: 10.1002/14651858.CD013166.pub3

Low‐intensity shockwave therapy for erectile dysfunction

Onuralp Ergun 1,2,✉, Kwangmin Kim 3, Myung Ha Kim 4, Eu Chang Hwang 5, Yooni Blair 6, Ahmet Gudeloglu 7, Sijo Parekattil 8, Philipp Dahm 1,2
Editor: Cochrane Central Editorial Service
PMCID: PMC12257276  PMID: 40654049

Abstract

Rationale

Low‐intensity shockwave therapy (LiSWT) is a new way of treating erectile dysfunction using sound waves to help improve blood flow to the penis. No existing systematic reviews comparing LiSWT to placebo or other therapies for treating erectile dysfunction have used rigorous Cochrane methodology. Many existing studies appear to be of poor methodological quality, and several trials are ongoing, reflecting an evolving evidence base. Therefore, it is unclear whether LiSWT truly helps men who have erectile dysfunction. Furthermore, there is very limited focus on patient‐important outcomes in the existing systematic reviews. In this comprehensive Cochrane review, we compared LiSWT to sham therapy to evaluate its efficacy and safety.

Objectives

To evaluate the benefits and harms of low‐intensity shockwave therapy for erectile dysfunction in men compared to sham treatment.

Search methods

We performed a comprehensive search of the Cochrane Library, MEDLINE, Embase, Scopus, and two trial registries up to 7 July 2024. We applied no restrictions on publication status or language.

Eligibility criteria

We included randomized controlled trials (RCTs) that compared LiSWT to either sham or no treatment. We excluded trials involving people with prior kidney transplants or who had surgical procedures to remove the prostate gland (i.e. radical prostatectomy).

Outcomes

Critical outcomes were erectile function, discontinuation from treatment, and treatment‐related adverse events; important outcomes were patient/partner satisfaction, penile rigidity, and quality of sexual life. We assessed all outcomes in the short term (≤ 3 months) and long term (> 3 months).

Risk of bias

We assessed the risk of bias using Cochrane's risk of bias assessment tool (RoB1).

Synthesis methods

We performed statistical analyses following Cochrane Handbook of Systematic Reviews of Interventions guidance. We synthesized results for each outcome using meta‐analysis using a random‐effects model. We used GRADE to assess the certainty of evidence.

Included studies

We focused on RCTs that applied LiSWT treatment utilizing electrohydraulic, electromagnetic, or piezoelectric energy. We included 21 RCTs, including 1357 randomized participants (men aged 39 to 65 years old with erectile dysfunction between 3 and 68 months); 16 were published in full text, and the rest as abstract proceedings. The baseline International Index of Erectile Function‐Erectile Function domain (IIEF‐EF) scores of participants in these studies ranged from seven to 20. Based on this scale, most men had mild‐to‐moderate (12 to 16) and mild (17 to 21) erectile dysfunction.

Synthesis of results

We included 21 RCTs that randomized 1357 participants. The certainty of the evidence for reported outcomes was low, mostly due to inconsistency, imprecision, and study limitations.

Erectile function

Based on the IIEF‐EF scale (6 to 30; higher score indicates higher erectile function; minimal clinically important difference (MCID): 4 point change), LiSWT, compared to sham treatment, may have a small effect on erectile function in the short term (mean difference (MD) 3.89 points higher, 95% confidence interval (CI) 2.89 higher to 4.89 higher; I2 = 62%; 15 studies, 937 participants; low‐certainty evidence). However, based on the selected MCID, this small effect may not be clinically important. In the long term, it may improve erectile function (MD 5.25 points higher, 95% CI 2.47 higher to 8.04 higher; I2 = 87%; 5 studies, 276 participants; low‐certainty evidence).

Discontinuation from treatment

LiSWT, compared to sham treatment, may have little to no effect on discontinuation from treatment in the short term (RR 0.77, 95% CI 0.47 to 1.27 higher; I2 = 0%; 17 studies, 1132 participants; low‐certainty evidence). This corresponds to 15 fewer (34 fewer to 17 more) discontinuations from treatment with the use of LiSWT per 1000 patients. There were no studies with an active treatment period longer than three months; therefore, we found no eligible data on this outcome in the long term.

Treatment‐related adverse events

LiSWT, compared to sham treatment, may have little to no effect on treatment‐related adverse events in the short term (risk difference (RD) 0.00, 95% CI −0.01 to 0.02; I2 = 0%; 20 studies, 1400 participants; low‐certainty evidence). Long term, it may also have little to no effect on treatment‐related adverse events (RD 0.00, 95% CI −0.02 to 0.02; I2 = 0%; 6 studies, 411 participants; low‐certainty evidence).

Patient/partner satisfaction

We found no evidence on patient or partner satisfaction in either the short or long term.

Penile rigidity

Based on the Erectile Hardness Scale (EHS) (1 to 4; higher score indicates higher penile rigidity; MCID: 1 point change), LiSWT compared to sham treatment may improve penile rigidity in the short term (MD 1.06 points higher, 95% CI 0.83 higher to 1.28 higher; I2 = 53%; 4 studies, 252 participants; low‐certainty evidence). In the long term, it may have a small improving effect on penile rigidity (MD 0.91 points higher, 95% CI 0.36 higher to 1.46 higher; I2 = 89%; 3 studies, 169 participants; low‐certainty evidence). However, based on the selected MCID, this small effect may not be clinically important.

Sexual quality of life

We found no evidence on sexual quality of life in either the short or long term.

Authors' conclusions

LiSWT may have a small effect on erectile function in the short term, although it may not be perceived to be clinically important by men with erectile dysfunction. It may improve erectile function in the long term. There may be little to no difference in treatment discontinuations in the short term. Since all eligible trials applied a treatment duration of three months or less, we found no data to compare treatment discontinuations in the long term. LiSWT may have little to no effect on treatment‐related adverse events in the short or long term, and may improve penile rigidity in the short term. In the long term, LiSWT may have a small improving effect on penile rigidity that may not be clinically important. We found no evidence on patient/partner satisfaction or sexual quality of life, either short or long term. The certainty of evidence was low for all outcomes due to shortcomings in the methodology of the included studies. Several studies were industry‐funded, mainly by device makers.

Funding

This Cochrane review had no dedicated funding.

Registration

Protocol (2023): doi.org/10.1002/14651858.CD013166.pub2

Plain language summary

Is low‐intensity shockwave therapy effective and safe for treating erectile dysfunction?

Key messages

  • Low‐intensity shockwave therapy may improve erections in the long term.

  • Low‐intensity shockwave therapy may improve the firmness and stiffness of the penis (penile rigidity) in the short term.

  • Treatment‐related side effects and early discontinuation of treatment due to side effects are uncommon in the short term.

What is erectile dysfunction ?

Erectile dysfunction is a common issue where a man has difficulty having or keeping an erection during sexual intercourse. It can be caused by many things, such as other health conditions, medical treatments (such as medicines or surgery on the prostate), unhealthy lifestyles (such as smoking, poor diet, and lack of exercise), and depression and anxiety.

How is erectile dysfunction treated?

There are different ways to treat erectile dysfunction. First, doctors might suggest lifestyle changes, such as exercising more, eating a balanced diet, or stopping smoking. If these do not work, doctors might suggest some medicines. Sometimes, if the problem is more about feelings or relationships with sexual partners, doctors might suggest talking to a therapist. There are other treatments, such as devices, injections, or surgeries. In this Cochrane review, we are looking at a new treatment method using shockwaves.

What is shockwave therapy?

Low‐intensity shockwave therapy uses sound waves to help blood flow better to the penis, which can help with erections. It is a simple treatment. A doctor uses a small device on different parts of the penis. The treatment does not hurt, and no medicine is needed to numb the area. Treatment takes about 15 to 20 minutes and happens several times over a span of weeks.

The term low‐intensity shockwave therapy highlights the safe nature of the therapy. High‐intensity shockwaves are strong and used for breaking things like kidney stones, but low‐intensity waves are soft and effective enough to work without causing harm.

What did we want to find out?

We wanted to know if low‐intensity shockwave therapy works better than a sham treatment (a device that pretends to use shockwaves). We looked at:

  • how well shockwave therapy helps with erections;

  • whether people stop shockwave therapy earlier than sham therapy earlier;

  • if there are any unwanted effects;

  • if patients and their partners are happy with the treatment results;

  • if shockwave therapy makes the penis more rigid; and

  • if shockwave therapy makes sexual life better.

What did we do?

We searched for all the medical studies that compared low‐intensity shockwave therapy to a sham treatment in men with erectile dysfunction. We checked the results of these studies and summarized the results and rated our confidence in them based on factors such as how well they performed.

What did we find?

We found 21 studies with 1357 men who received either low‐intensity shockwave therapy or the sham treatment. These men were between the ages of 39 and 65 and had erectile dysfunction for between 3 and 68 months.

Main results

We found that in the short term (3 months or less), low‐intensity shockwave therapy may have a small improving effect on erections, but that effect may not be big enough for men to notice. In the long term (more than 3 months), it may improve erections. In the short term, it may improve how rigid the penis gets. In the long term, it may also have a small effect on how rigid the penis gets, but once again this effect may not be big enough for men to notice. All treatments were only used in the short term, but some results were reported in the long term. Both in the short term and long term, low‐intensity shockwave therapy may have little to no effect on side effects from treatment or discontinuing treatment. We did not find any information on patients' and their partners' happiness with the treatment results or about their sexual lives.

What are the limitations of the evidence?

We have little confidence in these results, mainly because:

  • the studies were not done very well;

  • the evidence does not cover all the people, treatments, or endpoints we were interested in;

  • the studies were done on men with erectile dysfunction and used different ways of delivering shockwaves; and

  • the results were very different in each study.

Nine of the 21 studies received money from companies that make the devices that deliver shockwave treatment. Five studies said they did not receive any money from industry, and the rest of the studies did not state if they received any money or not.

How up to date is this evidence?

This review is current to 7 July 2024.

Summary of findings

Summary of findings 1. Low‐intensity shockwave therapy for erectile dysfunction (short term).

Low‐intensity shockwave therapy for erectile dysfunction (short term)
Patient or population: men at 18 years of age or older with organic or mixed erectile dysfunction
Setting: outpatient setting
Intervention: low‐intensity shockwave therapy (LiSWT)
Comparison: sham treatment
Outcomes* Anticipated absolute effects** (95% CI) Relative effect
(95% CI) No. of participants
(studies) Certainty of the evidence
(GRADE)*** Interpretation
Risk with sham Risk difference with LiSWT
Erectile function
Assumed MCID: 4 point change in IIEF‐EF score (6 to 30 scale; higher means better)
Mean IIEF‐EF score ranged from 8.6 to 20.9. MD 3.89 points higher
(2.89 higher to 4.89 higher)
— 937
(15 RCTs)
⊕⊕⊝⊝ 
Lowa,b There may be a small effect on erectile function. However, based on the selected MCID, this small effect may not be clinically important.
Discontinuation from treatment
Assumed MCID: 5% absolute change
64 per 1000 15 fewer per 1000
(34 fewer to 17 more)
RR 0.77
(0.47 to 1.27)
1132
(17 RCTs)
⊕⊕⊝⊝ 
Lowa,c LiSWT may have little to no effect on discontinuation from treatment between LiSWT and sham treatment.
Treatment‐related adverse events
Assumed MCID: 5% absolute change
7 per 1000 RD 0.0
(−0.01 to 0.02)
1400
(20 RCTs)
⊕⊕⊝⊝ 
Lowa,d LiSWT may have little to no effect on treatment‐related adverse events between LiSWT and sham treatment.
Patient/partner satisfaction — — — — — We found no evidence on how LiSWT may affect patient/partner satisfaction.
Penile rigidity
Assumed MCID: 1 point change in EHS score (1 to 4 scale; higher means better)
Mean EHS score ranged from 1.4 to 2.4. MD 1.06 points higher
(0.83 higher to 1.28 higher)
— 252
(4 RCTs)
⊕⊕⊝⊝ 
Lowa,c LiSWT may improve penile rigidity compared to sham treatment.
Sexual quality of life — — — — — We found no evidence on how LiSWT may affect sexual quality of life.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
**Analyzed using random‐effects models because of heterogeneity. 
Follow‐up duration is calculated as a weighted average of studies in each meta‐analysis. 
Abbreviations: CI: confidence interval; EHS: erectile hardness score; IIEF‐EF: international index of erectile function‐erectile function domain; LiSWT: low‐intensity shockwave therapy; MCID: minimal clinically important difference; MD: mean difference; RCT: randomized controlled trial; RD: risk difference; RR: risk ratio
***GRADE Working Group grades of evidence 
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

aDowngraded by one level for study limitations: unclear or high risk of bias in half or more domains.
bDowngraded by one level for clinically important, serious inconsistency. Imprecision caused by a wide CI crossing the assumed MCID threshold contributed to this decision to rate down once. 
cDowngraded by one level for clinically important, serious imprecision: wide CI crossing the MCID threshold once.
dDowngraded by one level for clinically important, serious imprecision: wide CI crossing the null value once.

Summary of findings 2. Low‐intensity shockwave therapy for erectile dysfunction (long term).

Low‐intensity shockwave therapy for erectile dysfunction (long term)
Patient or population: men at 18 years of age or older with organic or mixed erectile dysfunction
Setting: outpatient setting
Intervention: low‐intensity shockwave therapy (LiSWT) 
Comparison: sham treatment
Outcomes* Anticipated absolute effects** (95% CI) Relative effect
(95% CI) No. of participants
(studies) Certainty of the evidence
(GRADE)*** Interpretation
Risk with sham Risk difference with LiSWT
Erectile function
Assumed MCID: 4‐point change in IIEF‐EF score (6 to 30 scale; higher means better)
Mean IIEF‐EF scores ranged from 8 to 19.8 MD 5.25 points higher
(2.47 higher to 8.04 higher)
— 276
(5 RCTs)
⊕⊕⊝⊝ 
Lowa,b LiSWT may improve erectile function compared to sham treatment.
Discontinuation from treatment
Assumed MCID: 5% absolute change
— — — — — We found no evidence on how LiSWT may affect discontinuation from treatment.c
Treatment‐related adverse events
Assumed MCID: 5% absolute change
0 per 1000 RD 0.0
(−0.02 to 0.02)
411
(6 RCTs)
⊕⊕⊝⊝ 
Lowa,d LiSWT may have little to no effect on treatment‐related adverse events between LiSWT and sham treatment.
Patient/partner satisfaction — — — — — We found no evidence on how LiSWT may affect patient/partner satisfaction.
Penile rigidity
Assumed MCID: 1 point change in EHS score (1 to 4 scale; higher means better)
Mean EHS score ranged from 1.3 to 2.4. MD 0.91 points higher
(0.36 higher to 1.46 higher)
— 169
(3 RCTs)
⊕⊕⊝⊝ 
Lowa,b LiSWT may have a small effect on penile rigidity. However, based on the selected MCID, this small effect may not be clinically important.
Sexual quality of life — — — — — We found no evidence on how LiSWT may affect sexual quality of life.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
**Analyzed using random‐effects models because of heterogeneity.
Follow‐up duration is calculated as a weighted average of studies in each meta‐analysis. 
Abbreviations: CI: confidence interval; EHS: erectile hardness score; IIEF‐EF: international index of erectile function‐erectile function domain; LiSWT: low‐intensity shockwave therapy; MCID: minimal clinically important difference; MD: mean difference; RCT: randomized controlled trial; RD: risk difference; RR: risk ratio
***GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

aDowngraded by one level for study limitations: unclear or high risk of bias in half or more domains.
bDowngraded by one level for clinically important, serious inconsistency. Imprecision caused by a wide CI crossing the assumed MCID threshold contributed to this decision to rate down once. 
cThere were no studies with a treatment period longer than 3 months. Therefore, we also found no data for this outcome.
dDowngraded by one level for clinically important, serious imprecision: wide CI crossing the null value once.

Background

Low‐intensity shockwave therapy (LiSWT) is a newer way of treating erectile dysfunction. In this Cochrane review, we compared LiSWT to sham treatment to evaluate its efficacy and safety.

Description of the condition

Erectile dysfunction is defined as the consistent or recurrent inability to attain, or maintain, or attain and maintain a penile erection sufficient for sexual satisfaction, satisfactory performance, or both [1]. Erectile dysfunction has an estimated prevalence of approximately 40% in men between 40 and 49 years old, and up to 90% in men aged 70 years and older [2]. Studies suggest that erectile dysfunction is becoming more prominent in men younger than 40 years, with reported prevalence rates between 10% and 16% [3, 4].

Risk factors include the presence of two or more medical conditions in a patient at the same time (medical comorbidities), such as diabetes mellitus, cardiovascular disease (conditions affecting the heart or blood vessels), hypertension (a condition where the force of blood against the artery walls is consistently too high), obesity, hyperlipidemia (abnormally high levels of any or all lipids or lipoproteins in the blood), metabolic syndrome (a combination of several medical issues), abdominal‐pelvic interventions, benign prostatic hyperplasia (a condition where the prostate gland grows larger, potentially causing urinary problems), and psychiatric disorders [5]. Medications used to treat these conditions may also contribute to erectile dysfunction. Socioeconomic status may play a role, in that men from low socioeconomic environments are at increased risk of erectile dysfunction and tend to seek less counsel [6]. Smoking, medications, and hormonal factors are other well‐defined risk factors [7, 8].

The European Association of Urology Guidelines on Sexual and Reproductive Health define three categories for erectile dysfunction: organic (i.e. caused by physical or medical factors, rather than psychological ones), psychogenic (i.e. one that originates from the brain instead of other physical organs), and mixed [9]. Most cases of erectile dysfunction are classified as mixed type, given they usually involve both organic and psychological factors.

Diagnosis

Evaluation for erectile dysfunction starts with the person's history and a physical examination. Evaluation of a patient's partner in the same way can also be helpful. The history should include past medical, psychological, and sexual issues. The International Index of Erectile Function (IIEF) is widely used to assess the severity of erectile dysfunction [10]. It is a patient‐targeted questionnaire consisting of five domains: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. Depending on the response, men can be classified as having severe (5 to 7 points), moderate (8 to 11 points), mild‐to‐moderate (12 to 16 points), mild (17 to 21 points), or no erectile dysfunction (22 to 25 points). A complementary method to assess erectile rigidity is called Erection Hardness Score (EHS), developed by Goldstein and colleagues in 1998 during a sildenafil dose‐response trial [11].

Additional laboratory tests that may aid in erectile dysfunction diagnosis and its cause (etiology) include total blood count, serum chemistry, fasting glucose, hemoglobin A1C, lipid profile, and morning levels of total testosterone to evaluate for synchronous hypogonadism (where both the testicles (in males) have reduced or impaired function, leading to diminished gonadal activity). Additional tests – such as serum‐free testosterone and serum luteinizing hormone – can be pursued should the testosterone level be found to be low. Meanwhile, another common etiology of erectile dysfunction is local treatment for prostate cancer in the form of radical prostatectomy (the removal of the entire prostate gland, the seminal vesicles and the vas deferens) and radiation therapy (external beam or brachytherapy), with or without adjuvant systematic androgen deprivation therapy.

The psychological aspect of erectile dysfunction can be challenging to diagnose, and a multi‐specialty approach can be initiated, involving sexual therapists, psychologists, and urologists [1].

Treatment

Treatment of erectile dysfunction should focus on patient‐important outcomes, and treatment success should not be based solely on recovering penile rigidity. Lifestyle modifications, such as weight‐loss programs and regular exercise, have resulted in erectile dysfunction improvement, and thus should be the first recommendation to men presenting with erectile dysfunction [12]. Interventions directed toward cardiovascular health are also thought to be beneficial [13]. If there are suitable alternatives, beta blockers, thiazide diuretics, and other medications known for their erectile dysfunction‐exacerbating features should be discontinued [14]. Psychosexual therapy, including anxiety reduction, interpersonal therapy, behavioral therapy, couples' communication, and sexual skills training, have helped in ameliorating psychosexual barriers and alleviating erectile dysfunction [15].

After conservative methods have failed, or often concurrently with these methods, pharmacological therapies are offered. Phosphodiesterase‐5 inhibitors (PDE‐5i) are often the first‐line treatment [16], notably sildenafil, tadalafil, and vardenafil. These oral medications are easy to use and mostly effective, but studies show limitations [17]. These include interaction with a variety of other medications (antidepressant, antifungal, antiretroviral, and antihypertensive medications) and risk of hypotension with concomitant use of nitrates [18]. Other commonly used modalities for erectile dysfunction are vacuum constriction devices, intraurethral prostaglandin suppositories, intracavernosal injection therapy, and surgical placement of a penile prosthesis [19]. Several of these agents have also been used in post‐prostatectomy rehabilitation for erectile dysfunction, although with limited success rates [20]. Other treatments, such as ginseng, which are not regulated by the US Food and Drug Administration, do not appear to be effective [21].

An established technology, shockwave therapy (SWT), has recently been used for erectile dysfunction, with what are described as promising results [22, 23]. Although multiple studies have yielded conflicting results about whether the intervention actually works, direct‐to‐consumer marketing of this treatment has resulted in relatively widespread use [24].

Description of the intervention and how it might work

Since the 1980s, SWT has been widely used to treat renal stones. It has also been adapted for different diseases, such as musculoskeletal disorders, myocardial infarction, nonhealing wounds, plantar fasciitis, Peyronie's disease, and erectile dysfunction [25, 26, 27, 28]. A shockwave is defined as a wave that propagates through a medium, causing a characteristic rapid rise time and high positive peak pressure. This pressure is thought to cause neovascularization (natural formation of new blood vessels) and tissue regeneration.

Shockwaves can be categorized as electrohydraulic shockwaves, electromagnetic shockwaves, piezoelectric shockwaves, and radial shockwaves [29]. These forms of shockwaves are produced with several commercially available generators. These generators have a probe (i.e. a wand‐like device) that is usually applied systematically to all sections of the left and right corpora cavernosa (which contain the expandable erectile tissue responsible for erections), namely, the two crura (which represent the tips of the corpora), the root (where the two corpora come together), the middle part, and the tip of the penile shaft during a typical treatment session [30]. The sessions usually take 15 to 20 minutes. The number and frequency of sessions varies between protocols – from once every week for four weeks to once every week for 12 weeks and possibly even more – depending on the manufacturer's recommendations, physician preference, and patient availability [31].

SWT for erectile dysfunction is generally referred to as LiSWT, focused shockwave therapy (FSWT), or extracorporeal shockwave therapy (ESWT). For the different types of shockwaves, the commercially available generators include the following:

  • electrohydraulic shockwaves: ED1000 (Medispec, Yehud, Israel); UroGold 100 (MTS Medical UG, Konstanz, Germany);

  • electromagnetic shockwaves: Duolith SD1 Ultra (Storz Medical AG, Tägerwilen, Switzerland); RENOVA (Direx Group, Wiesbaden, Germany); ARIES 2TM (Dornier MedTech GmbH, Wessling, Germany); MT 2000H (Urontech Korea, Hwaseong, Korea); Intelect Focus Shockwave (Chattanooga, Dallas, TX, USA); and

  • piezoelectric shockwaves: PiezoWave 2 (Richard‐Wolf GmbH, Knitlingen, Germany) [29].

Our study will focus on LiSWT as an erectile dysfunction therapy that includes the application of shockwaves to the penile shaft using an electrohydraulic, an electromagnetic, or a piezoelectric generator, with any treatment protocol (frequency and duration of treatment, energy densities, pulses per minute, etc.). The use of radial shockwaves in erectile dysfunction is a relatively newer field with limited availability compared to LiSWT [32]; this treatment is beyond the scope of our study.

Two reviews of LiSWT for erectile dysfunction have highlighted that clinical trials in this field have different protocols, devices, settings, types of shockwaves, and even different nomenclature for the procedures used [27, 29]. An example of the non‐standardized nomenclature is the term 'linear' SWT. Some studies use this term to describe the linear alignment of the corpora of the penis and the correspondingly linear application of LiSWT. Other studies use the term 'linear' therapy to refer to the extent of tissues targeted with one pulse from the probe, and contrast it to 'focused' therapy which targets a smaller area [33, 34]. The terminological diversity in this research area detracts from the power of the evidence.

Adverse effects of the intervention

LiSWT for erectile dysfunction has mostly been reported to be safe with few and relatively minor treatment‐related adverse effects [35]. The most commonly encountered treatment‐related adverse effects seem to be bruising and hematoma and usually require no intervention [36]. Hematuria (presence of blood or red blood cells in the urine), infection of penile skin, painful erection, and difficulty having intercourse secondary to infection or pain might be other potential treatment‐related adverse effects.

Shockwaves are thought to be able to induce neovascularization through a cascade of reactions due to focused energy. Shockwaves are believed to exert physical forces on tissues in two ways. First, there is mechanical stress from exposure to the high peak pressure shockwave. Second, in liquids, shockwaves form cavitation bubbles, which are focal areas of vaporization of the liquid. These cavities then collapse when subjected to high pressures, resulting in local trauma and neovascularization [37]. Nurzynska and colleagues also found that shockwaves increase vascular endothelial growth factor (VEGF) secretion and VEGF receptor sensitivity in myocardial cells, which could also induce neovascularization [38]. The mechanism of action of this modality is suggested to involve vascular regeneration and also nerve repair. Peng and colleagues indicated that the application of LiSWT after nerve surgery promoted nerve regeneration and improved the functional outcomes [39]. Underlying mechanisms include an increase in neurotrophic factors, Schwann cell activation, and cellular signaling activation for cell activation and mitosis induced by LiSWT. These results, together with other studies [40], suggest that this treatment may also be useful in men after prostatectomy with erectile dysfunction due to injury to the neurovascular bundles.

Why it is important to do this review

Although LiSWT may be a potentially new and valuable treatment option for erectile dysfunction, which may reverse some of the underlying causes [23], it remains unclear how effective it really is. While existing systematic reviews compare LiSWT to placebo or other therapies used to treat erectile dysfunction [27, 41], none so far has used the same rigorous methodology expected of Cochrane reviews, including the application of GRADE. Given the limited methodological quality of the studies that have been summarized in existing systematic reviews, including a certainty of evidence rating on a per‐outcome basis appears paramount. In addition, there are several ongoing trials, reflecting a fast‐evolving evidence base, making a re‐assessment of the evidence timely and relevant. Considering the high prevalence of erectile dysfunction, and the impact on men's health, the benefits and harms of LiSWT should be carefully assessed. Assessing and quantifying the existing evidence using Cochrane review methodology will help to guide patients, practitioners, and policymakers, and help determine the role of LiSWT in treating erectile dysfunction.

Objectives

To evaluate the benefits and harms of low‐intensity shockwave therapy for erectile dysfunction in men compared to sham treatment.

Methods

We applied a rigorous methodology to assess LiSWT, with a focus on patient‐important outcomes, a comprehensive literature search, and the use of the GRADE approach reported in the summary of findings tables. This review was done in accordance with a pre‐registered Cochrane protocol [42]. We have based parts of the Methods and Supplementary material 1 sections of the Cochrane protocol on a standard template established by Cochrane Metabolic and Endocrine Disorders. We used guidance from clinical experts to define the methods in this review. We followed the Methodological Expectations for Cochrane Intervention Reviews (MECIR) when conducting the review [43], and PRISMA 2020 for the reporting [44].

Criteria for considering studies for this review

Types of studies

We included only randomized controlled trials (RCTs). We excluded pseudo‐randomized trials (i.e. those using alternating allocation), cross‐over trials (unless they reported results before the cross‐over was performed) [45], and cluster‐RCTs as they were not relevant to the clinical question of interest. We included studies regardless of their publication status or the language of publication.

Types of participants

We included people with organic or mixed erectile dysfunction who were 18 years of age or older.

Diagnostic criteria for erectile dysfunction

Men with primary organic and mixed erectile dysfunction, as identified by their clinical history, who are interested in seeking treatment.

Variety in diagnostic criteria, disease severity, or both may produce significant variability in the clinical characteristics of the participants included and in the results obtained (which we attempted to investigate through subgroup analysis). We deemed trials involving participants with comorbid disorders eligible for inclusion, as long as the primary focus of the intervention was erectile dysfunction.

Exclusion criteria

We excluded trials with people with iatrogenic causes of erectile dysfunction (i.e. caused by any medical activity, such as pelvic surgery, radiation, or antiandrogen therapy); neurological or primary psychogenic causes of erectile dysfunction; erectile dysfunction secondary to anatomic anomalies or hypogonadism. We excluded studies that target men who develop erectile dysfunction after a kidney transplant or radical prostatectomy.

Types of interventions

We assessed trials that compared LiSWT to either sham treatment or no treatment.

Our review included the application of shockwaves to the penile shaft under any treatment protocol (frequency and duration of treatment, energy densities, pulses per minute, etc.) utilizing:

  • electrohydraulic generators;

  • electromagnetic generators; and

  • piezoelectric generators.

We excluded trials utilizing "radial" SWT for erectile dysfunction as the energy dispersion and tissue penetration with this method falls outside the scope of our review [46].

Concomitant interventions had to be the same in the experimental and comparator groups to establish fair comparisons.

Minimum duration of intervention and follow‐up

Given the lack of consensus about minimum treatment standards (in terms of number of applications, frequency and duration of LiSWT treatment, and energy density), we included all treatment protocols. We also included studies regardless of their length of follow‐up.

Outcome measures

We did not exclude studies because one or several of our critical or important outcome measures were not reported in the publication. We attempted to contact the study authors to obtain any missing outcome information. Below we have listed our critical and important outcomes, followed by the details of their definitions, timings of assessment, and the MCIDs.

Since the publication of the Cochrane protocol [42], we have decided to rename 'discontinuation of treatment' and 'adverse events' outcomes to 'discontinuation from treatment' and 'treatment‐related adverse events', respectively. We considered the latter versions to be more presentable and clinically more accurate.

Critical outcomes

  • Erectile function

  • Discontinuation from treatment

  • Treatment‐related adverse events

Important outcomes

  • Patient/partner satisfaction

  • Penile rigidity

  • Quality of sexual life

Method and timing of outcome measurement
Erectile function
  • We evaluated this outcome with validated questionnaires, such as the erection domain of IIEF (IIEF‐EF; [10]), IIEF‐5 [47], or the IIEF question 15 [10]. IIEF‐EF (6‐item questionnaire; scale 6 to 30; higher scores reflect higher erectile function) was the most commonly used questionnaire.

  • We used an MCID of 4‐point change in IIEF‐EF decided with a panel discussion among study authors using clinical expert opinions, utilizing prior Cochrane reviews with similar scopes [48], and as suggested by other studies within the literature [49].

Discontinuation from treatment
  • We took into account any cause of treatment discontinuation after participants were randomized to intervention/comparator groups and during the active treatment period.

  • We considered a 5% absolute difference in discontinuation rates from treatment as the MCID.

Treatment‐related adverse events
  • We focused on treatment‐related adverse events reported in trials that were assumed/reported to be secondary to the intervention; namely, penile bruising, hematoma, hematuria, infection of penile skin, painful erections, and urinary retention.

  • We considered a 5% absolute difference in treatment‐related adverse event rates as the MCID.

Patient/partner satisfaction
  • We attempted to use data obtained by validated questionnaires; for example, the Watts Sexual Function Questionnaire [50], but did not find any data for this outcome.

  • We planned to use MCIDs as reported in the literature for these questionnaires; in the absence of published thresholds, we planned to derive a relevant threshold using a distribution‐based methodological approach [51].

Penile rigidity
  • We assessed this outcome with validated questionnaires, such as the Erectile Hardness Score (EHS) (1‐item tool; scale 1 to 4; higher scores reflect higher penile rigidity) [11].

  • We used an MCID of 1‐point change on the EHS [52].

Quality of sexual life
  • We attempted to use data obtained by validated questionnaires, such as the Sexual Quality of Life Questionnaire Male (SQoL‐M) [53], but did not find any data for this outcome.

  • We planned to use MCIDs as reported in the literature for these questionnaires; in the absence of published thresholds, we planned to derive a relevant threshold using a distribution‐based methodological approach [51].

We reviewed all outcomes at short term (≤ 3 months) and long term (> 3 months). There were no study protocols over three months; therefore, we found no eligible studies reporting the discontinuation from treatment outcome in the long term.

Main outcomes for the summary of findings tables

We presented summary of findings tables for both short‐term and long‐term outcomes, reporting all the outcomes in the following order of importance:

  • erectile function;

  • discontinuation from treatment;

  • treatment‐related adverse events;

  • patient/partner satisfaction;

  • penile rigidity; and

  • quality of sexual life.

Search methods for identification of studies

We performed a comprehensive search with no restriction on the language of publication or publication status (see Supplementary material 1). We updated our search every three months prior to publication. The latest search date was 7 July 2024.

Electronic searches

We searched the following sources from the inception of each database.

We also searched the following sources.

  • ClinicalTrials.gov (www.ClinicalTrials.gov)

  • World Health Organization (WHO) International Clinical Trials Registry Platform (apps.who.int/trialsearch)

  • Grey Literature Report (https://catalog.nyam.org/)

If we detected additional relevant keywords during any of the electronic or other searches, we modified the electronic search strategies to incorporate these terms and document the changes.

Searching other resources

We tried to identify potentially eligible trials or ancillary publications based on the referenced studies in included trials, systematic reviews, meta‐analyses, and health technology assessment reports. We contacted the study authors or device manufacturers of ongoing trials, or both, for unpublished trials to identify any unpublished data that we may have missed in our search results.

Data collection and analysis

The data package is in Supplementary material 7.

Selection of studies

We used EndNote reference management software to identify and remove duplicate records [54]; and the Covidence software platform for study selection and data extraction [55]. Two review authors (OE, KK) independently scanned the abstract or title, or both, of the remaining records retrieved, to determine which studies we should assess further. Working independently, two review authors (OE, KK) then investigated all potentially relevant records in full text, mapped records to studies, and classified studies as included studies (see Table), excluded studies, studies awaiting classification, or ongoing studies, in accordance with the criteria for each provided in the Cochrane Handbook for Systematic Reviews of Interventions [56]. We resolved any discrepancies through consensus or recourse to a third review author (PD). If resolution of a disagreement was not possible, we designated the study as 'awaiting classification' (see Supplementary material 4), and attempted to contact the study authors for clarification. We documented reasons for the exclusion of studies that may have reasonably been expected to be included in the review in Supplementary material 3. We presented a PRISMA flow diagram (Figure) showing the process of study selection [44].

1. Overview of included studies.
Study LiSWT device Number of participants Treatment Baseline IIEF‐EF score Outcome with available data
Duration Protocol LiSWT mean (SD) Sham mean (SD)
Randomized LiSWT Sham
Chung 2022 Device: Duolith SD1 Ultra (Storz Medical AG, Tägerwilen, Switzerland); energy source: electromagnetic 60 30 30 6 weeks Number of shocks: 3000; energy: 0.25 mJ/mm2; frequency: 6 Hz; schedule: 12 treatments (2 sessions per week) 14.6 (3.8)a 14.8 (3.8)a Short term: erectile function; discontinuation of treatment; treatment‐related adverse events; penile rigidity
Long term: erectile function; treatment‐related adverse events; penile rigidity
Fojecki 2017 Device: PiezoWave 2 (Richard‐Wolf GmbH, Knitlingen, Germany); energy source: piezoelectric 126 63 63 10 weeks Number of shocks: 600; energy: 0.09 mJ/mm2; frequency: 5 Hz; schedule: 2 rounds of 5 weekly sessions 10.9 (NR) 11.5 (NR) Short term: erectile function; discontinuation from treatment; treatment‐related adverse events
Long term: treatment‐related adverse events
Harish 2017 NR 60 30 30 NR NR NR NR Short term: treatment‐related adverse events
Long term: treatment‐related adverse events
Kalyvianakis 2017 Device: ED1000 (Medispec, Yehud, Israel); energy source: electrohydraulic 46 30 16 9 weeks Number of shocks: 1500; energy: 0.09 mJ/mm2; frequency: 2.6 Hz; schedule: 12 treatments 13.8 (3.6) 14.6 (3.4) Short term: erectile function; discontinuation from treatment; treatment‐related adverse events
Long term: treatment‐related adverse events
Kalyvianakis 2022 Device: ARIES 2TM (Dornier MedTech GmbH, Wessling, Germany); energy source: electromagnetic 70 35 35 6 weeks Number of shocks: 5000; energy : 0.096 mJ/mm2; frequency: 5 Hz; schedule: twice‐weekly 14 (NR) 15 (NR) Short term: erectile function; discontinuation from treatment; treatment‐related adverse events
Kennady 2023 Device: Duolith SD1 Ultra (Storz Medical AG, Tägerwilen, Switzerland); energy source: electromagnetic 33 17 16 3 weeks Number of shocks: 3000; energy: 0.1 mJ/mm2; frequency: 5 Hz; schedule: twice‐weekly 10.8 (3.6)a 12.1 (3.3)a Short term: erectile function; discontinuation from treatment; treatment‐related adverse events
Kim 2020 Device: MT 2000H (Urontech Korea, Hwaseong, Korea); energy source: electromagnetic 96 46 49 6 weeks Number of shocks: 3000; energy: 0.2 mJ/mm2; frequency: 5 Hz; schedule: 2 sessions every week for 3 weeks, repeated after a 3‐week resting period 16.6 (3) 16.7 (3.2) Short term: erectile function; discontinuation from treatment; treatment‐related adverse events; penile rigidity
Kitrey 2016 Device: ED1000 (Medispec, Yehud, Israel); energy source: electrohydraulic 58 40 18 9 weeks Number of shocks: 1500; energy: 0.09mJ/mm2; frequency: 2 Hz; schedule: 12 treatments over 9 weeks (2 sessions per week) with a 3‐week no‐treatment interval 7 (median) (range 6 to 12) 8 (median) (range 6 to 12) Short term: erectile function; discontinuation from treatment; treatment‐related adverse events
Olsen 2015 Device: Duolith SD1 Ultra (Storz Medical AG, Tägerwilen, Switzerland); energy source: electromagnetic 112 51 54 5 weeks Number of shocks: 600; energy: 0.15 mJ/mm2; frequency: 5 Hz; schedule: 5 treatments over 5 weeks NR NR Short term: discontinuation from treatment; treatment‐related adverse events
Ong 2022 Device: PiezoWave 2 (Richard‐Wolf GmbH, Knitlingen, Germany); energy source: piezoelectric 51 27 24 4 weeks Number of shocks: 4000; energy: 0.15 mJ/mm2; frequency: 8 Hz; schedule: 4 treatments over 4 weeks 12 (median) (IQR 7) 10 (median) (IQR 8) Short term: erectile function; discontinuation from treatment; treatment‐related adverse events; penile rigidity
Long term: erectile function; treatment‐related adverse events; penile rigidity
Ortac 2021 Device: Duolith SD1 Ultra (Storz Medical AG, Tägerwilen, Switzerland); energy source: electromagnetic 66 44 22 4 weeks Number of shocks: 3000; energy: 0.2 mJ/mm2; frequency: 5Hz; schedule: 42 treatments over 4 weeks 20.32 (2.32) 19.68 (1.55) Short term: erectile function; discontinuation from treatment; treatment‐related adverse events
Long term: erectile function
Shendy 2021 Device: Intelect Focus Shockwave (Chattanooga, Dallas, TX, USA); energy source: electromagnetic 42 21 21 9 weeks Number of shocks: 3000; energy: 0.09 mJ/mm2; frequency: NR; schedule: 12 treatments over 9 weeks (2 sessions per week) with a 3‐week no‐treatment interval 12.75 (3.21) 12.75 (2.61) Short term: erectile function; discontinuation from treatment; treatment‐related adverse events
Spivak 2018 Device: ED1000 (Medispec, Yehud, Israel); energy source: electrohydraulic 50 36 14 6 weeks Number of shocks: 1500; energy: NR; frequency: NR; schedule: 12 sessions (6 sessions, twice a week in 3 consecutive weeks and repeated after 3 weeks) NR NR Short term: discontinuation from treatment; treatment‐related adverse events
Sramkova 2020 Device: PiezoWave 2 (Richard‐Wolf GmbH, Knitlingen, Germany); energy source: piezoelectric 60 30 30 2 weeks Number of shocks: 6000; energy: 0.16 mJ/mm2; frequency: NR; schedule: 4 sessions (2 sessions per week) 12.8 (3.9)a 13.1 (3.6)a Short term: erectile function; discontinuation from treatment; treatment‐related adverse events; penile rigidity
Srini 2015 Device: ED1000 (Medispec, Yehud, Israel); energy source: electrohydraulic 135 95 40 9 weeks Number of shocks: 300; energy: 0.15 mJ/mm2; frequency: 2 Hz; schedule: 12 treatments over 9 weeks (2 sessions per week) with a 3‐week no‐treatment interval 9.5 (NR) 9.2 (NR) Short term: erectile function; treatment‐related adverse events
Long term: erectile function
Vardi 2012 Device: ED1000 (Medispec, Yehud, Israel); energy source: electrohydraulic 67 46 21 9 weeks Number of shocks: 300; energy: 0.09 mJ/mm2; frequency: 2 Hz; schedule: 12 treatments over 9 weeks (2 sessions per week) with a 3‐week no‐treatment interval 12.6 (0.75) 11.5 (0.86) Short term: erectile function; discontinuation from treatment; treatment‐related adverse events
Vinay 2017 Device: NR; energy source: electrohydraulic 58 30 28 6 weeks Number of shocks: 1500; energy: 0.10 mJ/mm2; frequency: 5 Hz; schedule: 1 session per week 10 (3.9)a 10 (4.5)a Short term: erectile function; discontinuation from treatment
Vinay 2021 Device: RENOVA (Direx Group, Wiesbaden, Germany); energy source: electromagnetic 80 40 40 4 weeks Number of shocks: 5000; energy: 0.09 mJ/mm2; frequency: 2 Hz; schedule: 1 session per week 12 (median) (IQR 8 to 17) 13 (median) (IQR 8 to 17) Short term: erectile function; discontinuation from treatment; treatment‐related adverse events
Long term: treatment‐related adverse events
Xin 2017 NR 70 46 24 4 weeks Number of shocks: 5000; energy: NR; frequency: NR; schedule: 1 treatment session per week NR NR Short term: treatment‐related adverse events
Yang 2019 NR 60 40 20 4 weeks Number of shocks: NR; energy: NR; frequency: NR; schedule: 1 treatment session per week NR NR Short term: discontinuation from treatment; treatment‐related adverse events
Yee 2014 Device: ED1000 (Medispec, Yehud, Israel); energy source: electrohydraulic 70 36 34 9 weeks Number of shocks: 1500; energy: 0.09 mJ/mm2; frequency: 2 Hz; schedule: 12 treatments (2 sessions per week) with a 3‐week no‐treatment interval 10.2 (3.8) 10.2 (3.8) Short term: discontinuation from treatment; treatment‐related adverse events
Long term: erectile function; penile rigidity
Abbreviations: Hz: hertz; IIEF‐EF: International Index of Erectile Function ‐ Erectile Function domain; IIEF‐5: International Index of Erectile Function ‐ 5 question; IQR: interquartile range; LiSWT: low‐intensity shockwave therapy; mj/mm2: millijoules per square millimeter; NR: not reported; SD: standard deviation.

aBaseline IIEF‐5 scores reported instead of IIEF‐EF.

1.

1

PRISMA diagram illustrating the study selection process.

Data extraction and management

We developed a dedicated data extraction form, which we pilot tested on three studies (Chung 2022 [57]; Fojecki 2017 [58]; Harish 2017 [59]).

For studies that fulfilled the inclusion criteria, two review authors (OE, KK) independently extracted the following information and provided it in Supplementary material 2:

  • study design;

  • study dates (if dates were not available then this was reported as such);

  • study settings and country;

  • participant inclusion and exclusion criteria (e.g. severity of erectile dysfunction at baseline, prior treatments for erectile dysfunction, medical comorbidities);

  • participant details, baseline demographics (e.g. age, body mass index, severity of erectile dysfunction at baseline)

  • number of participants by study and by study arm;

  • details of relevant experimental and comparator interventions (e.g. energy density (mJ/mm2), duration and frequency of treatment, targeted spots on the penis, pulses per week, generator type used);

  • definitions of relevant outcomes, method and timing of outcome measurement, as well as any relevant subgroups;

  • study funding sources; and

  • primary investigators' declarations of interest.

We summarized the following information for all the included studies in Table:

  • device used for LiSWT;

  • energy source of the used LiSWT device;

  • number of participants in both groups;

  • treatment duration;

  • treatment protocol; and

  • baseline IIEF scores.

We extracted outcomes data relevant to this Cochrane review to calculate summary statistics and measures of variance. For dichotomous outcomes, we attempted to obtain numbers of events and totals to populate a 2 x 2 table, as well as summary statistics with corresponding measures of variance. For continuous outcomes, we attempted to obtain means and standard deviations or data necessary to calculate this information.

We resolved any disagreements by discussion, or, if required, by consultation with a third review author (PD).

We provided information (including trial identifiers) about potentially relevant ongoing studies in the Supplementary material 5.

We attempted to contact the authors of the included studies to obtain key missing data, if needed.

Dealing with duplicate and companion publications

In the event of duplicate publications, companion documents, or multiple reports of a primary study, we tried to maximize information yield by mapping all publications to unique studies and collecting all available data. We used the most complete data‐set aggregated across all known publications. In case of doubt, we gave priority to the publication reporting the longest follow‐up associated with our outcomes.

Risk of bias assessment in included studies

Two review authors (OE, KK) independently assessed the risk of bias in each included study. We resolved disagreements again, by consensus, or by consulting a third review author (PD).

We assessed risk of bias using Cochrane's risk of bias assessment tool [60]. We assessed the following domains:

  • random sequence generation (selection bias);

  • allocation concealment (selection bias);

  • blinding of participants and personnel (performance bias);

  • blinding of outcome assessment (detection bias);

  • incomplete outcome data (attrition bias);

  • selective reporting (reporting bias); and

  • other sources of bias.

We judged the risk of bias domains as either 'low risk', 'high risk', or 'unclear risk' and evaluated individual bias items as described in the Cochrane Handbook for Systematic Reviews of Interventions [61]. We presented risk of bias summary (Figure) and graph (Figure) figures to illustrate these findings.

2.

2

Risk of bias summary: review authors' judgments about each risk of bias item for each included study.

Footnotes
Green +: low risk of bias; Red ‐: high risk of bias; Yellow ?: unclear risk of bias.

3.

3

Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies.

For performance bias (blinding of participants and personnel) and detection bias (blinding of outcome assessment), we evaluated the risk of bias separately for each outcome.

We considered all outcomes similarly susceptible to performance bias.

We defined all outcomes except 'discontinuation of treatment' as susceptible to detection bias, thereby making blinding important.

We also assessed attrition bias (incomplete outcome data) on an outcome‐specific basis, and presented the judgment for each outcome separately when reporting our findings in the risk of bias figures.

We further summarized the risk of bias across domains for each outcome in each included study, as well as across studies and domains for each outcome, in accordance with the approach for summary assessments of the risk of bias presented in the Cochrane Handbook for Systematic Reviews of Interventions [60].

Measures of treatment effect

We expressed dichotomous data as a risk ratio (RR) with a 95% confidence interval (CI). For continuous outcomes measured on the same scale (e.g. IIEF‐EF), we estimated the intervention effect using the mean difference (MD) with 95% CI. For rare events, such as event rates below 1% or arms with no events, or both, we used the risk difference (RD). We used an MCID to identify the proportion of participants that experienced a clinically meaningful change. Changes in IIEF‐EF scores instead of end‐point IIEF‐EF scores were integrated into our analysis for three studies (Kennady 2023 [62]; Vardi 2012 [63]; Vinay 2017 [64]). We measured the change in IIEF‐EF score from the bar graphs by visual graphic analysis in the study (Vardi 2012).

Unit of analysis issues

The unit of analysis was the individual participant. We had no trial with more than two intervention groups.

Dealing with missing data

We attempted to obtain missing data from study authors, if feasible, and performed intention‐to‐treat analyses if data were available. Otherwise, we performed available‐case analyses. We investigated attrition rates (e.g. dropouts, losses to follow‐up and withdrawals), and critically appraised issues of missing data. We did not impute missing data.

Reporting bias assessment

We attempted to obtain study protocols to assess for selective outcome reporting.

For outcomes informed by 10 or more studies, we used funnel plots to assess small‐study effects, which we interpreted in a manner consistent with guidance in the Cochrane Handbook for Systematic Reviews of Interventions [56].

Synthesis methods

We summarized data using a random‐effects model and performed statistical analyses according to the statistical guidelines contained in the Cochrane Handbook for Systematic Reviews of Interventions [56]. For dichotomous outcomes, we used the Mantel‐Haenszel method; for continuous outcomes, we used the inverse variance method. We utilized Review Manager (RevMan) software to perform analyses [65].

We only performed meta‐analysis where this was meaningful; that is, when the treatments, participants, and outcomes were sufficiently similar. In the event of excessive heterogeneity unexplained by subgroup analyses, we would have provided a narrative description of the results of each study.

We identified heterogeneity (inconsistency) through visual inspection of the forest plots to assess the amount of overlap of CIs, and the I2 statistic, which quantifies inconsistency across studies, to assess the impact of heterogeneity on the meta‐analysis [66, 67]. We interpreted the I2 statistic as follows [68]:

  • 0% to 40%: may not be important;

  • 30% to 60%: may indicate moderate heterogeneity;

  • 50% to 90%: may indicate substantial heterogeneity;

  • 75% to 100%: considerable heterogeneity.

When we found heterogeneity, we attempted to determine possible reasons for it by examining individual study and subgroup characteristics.

Investigation of heterogeneity and subgroup analysis

We expected the following characteristics to introduce clinical heterogeneity and planned to perform subgroup analyses to investigate interactions.

  • Response to PDE‐5i (responders versus non‐responders): we based the decision to perform this subgroup analysis on studies suggesting greater effectiveness of LiSWT in PDE‐5i responders [41].

  • Baseline severity (mild versus mild‐to‐moderate versus moderate or severe erectile dysfunction): we based the decision to perform this subgroup analysis on studies suggesting that baseline erectile dysfunction severity might be a determinant of treatment response to LiSWT [69].

We used the test for subgroup differences in RevMan to compare subgroup analyses if there were sufficient studies [65]. We found no studies informing baseline severity.

Equity‐related assessment

We did not investigate health inequity in this review as we did not expect any included study to have inequity data.

Sensitivity analysis

We explored the influence of risk of bias on the effect size through a sensitivity analysis. We repeated our critical outcome analyses without the studies that were at high risk of bias for any domain. We performed sensitivity analyses on both short‐term and long‐term outcomes.

Certainty of the evidence assessment

We presented the overall certainty of the evidence for each outcome according to the GRADE approach, which takes into account five criteria: four related to internal validity (risk of bias, inconsistency, imprecision, publication bias), and one related to external validity, the directness of results [70]. For each comparison, two review authors (OE, PD) independently rated the certainty of evidence for each outcome as either 'high', 'moderate', 'low', or 'very low' using GRADEpro GDT software [71]. We resolved any discrepancies by consensus, or, if needed, through arbitration by a third review author (EH). For each comparison, we presented a summary of the evidence for the outcomes in a summary of findings table, which provided key information about: the best estimate of the magnitude of the effect in relative terms and absolute differences for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of the overall confidence in effect estimates for each outcome [72, 73]. If meta‐analysis was not possible, we presented the results in a narrative summary of findings table. We interpreted results using a minimally contextualized approach [74], and used GRADE narrative language to characterize the certainty of evidence and magnitude of effect [75].

The summary of findings tables present all six outcomes described in our published Cochrane protocol [42].

Consumer involvement

We received feedback from a consumer of LiSWT. The consumer was a patient who had personally received LiSWT. The consumer was not involved with any part of the conduct of this Cochrane review, but we asked them to provide feedback, which is in Supplementary material 8.

Results

Description of studies

Results of the search

Our comprehensive search yielded 4364 records. We found one additional record through other sources. After de‐duplication, we screened 4092 records and excluded 4046 at the title/abstract screening stage as irrelevant. We screened the full‐text manuscripts or re‐evaluated the full abstracts of the remaining 46 records, or both; one record was a duplicate record, and we excluded seven studies (nine records) for various reasons. We found 14 ongoing studies and one study is awaiting classification. We ultimately included 21 studies. Figure demonstrates the study screening and selection process as a PRISMA flow diagram.

Included studies

For details of the included studies, please refer to Table and Supplementary material 2.

Source of data

Sixteen of the included studies were published as full‐text articles (Chung 2022; Fojecki 2017; Kalyvianakis 2017 [76]; Kalyvianakis 2022 [77]; Kennady 2023; Kim 2020 [78]; Kitrey 2016 [79]; Olsen 2015 [80]; Ong 2022 [81]; Ortac 2021 [82]; Shendy 2021 [83]; Sramkova 2020 [84]; Srini 2015 [85]; Vardi 2012; Vinay 2021 [86]; Yee 2014 [87]), and the remaining five were abstract proceedings only (Harish 2017; Spivak 2018 [88]; Vinay 2017; Xin 2017 [89]; Yang 2019 [90]). All studies were published in English.

We attempted to contact the corresponding authors of 15 included trials to obtain additional information and data on the results, where relevant, but only six replied (Chung 2022; Fojecki 2017; Ong 2022; Vinay 2017; Xin 2017; Yee 2014). Details of communication attempts and responses are in the notes section of each study in Supplementary material 2.

Study design and settings

All but one study were parallel‐group RCTs. One study was a cross‐over trial that was included to inform short‐term outcomes before the cross‐over was performed (Kennady 2023). All but three studies (Ortac 2021; Sramkova 2020; Vinay 2017), were described as 'double‐blinded' per original study titles.

Most studies were performed in Europe (Denmark, Greece, Turkey, Czech Republic, Spain); other studies were from Australia, India, South Korea, Israel, Malaysia, Egypt, Russia, China, and the USA. Fourteen studies were conducted in a single center (Chung 2022; Harish 2017; Kalyvianakis 2017; Kalyvianakis 2022; Kennady 2023; Ong 2022; Ortac 2021; Spivak 2018; Sramkova 2020; Srini 2015; Vardi 2012; Vinay 2017; Vinay 2021; Yee 2014), six were multicenter (Fojecki 2017; Kim 2020; Olsen 2015; Shendy 2021; Xin 2017; Yang 2019), and one had insufficient information on the setting characteristics (Kitrey 2016).

Studies took place from July 2009 to October 2023.

Participants

There were 1357 randomized participants. The mean age of participants ranged between 39.8 and 65.1 years. Three studies did not report the mean age of their participants (Harish 2017; Spivak 2018; Vinay 2017).

Average erectile dysfunction duration of the participants ranged broadly from 3 to 68 months. Nine studies did not report erectile dysfunction duration of their population (Fojecki 2017; Harish 2017; Kim 2020; Ortac 2021; Shendy 2021; Spivak 2018; Vinay 2017; Xin 2017; Yang 2019). Baseline mean IIEF‐EF scores ranged from 7 to 20. Four studies reported baseline IIEF‐5 scores rather than IIEF‐EF scores (Chung 2022; Kennady 2023; Sramkova 2020; Vinay 2017). No study included participants based on their baseline erectile dysfunction severity. There was only one study reporting baseline sexual quality of life of their participants (Fojecki 2017).

Most studies did not specify their participants' PDE‐5i response status. Two studies reported including participants who responded to prior PDE‐5i therapy (Fojecki 2017; Harish 2017). One study stated that they included participants who were non‐responders to PDE‐5i therapy (Vinay 2017).

Interventions and comparators

Treatment protocols differed across studies. Active intervention duration ranged from 2 to 9 weeks. Most studies established a four‐week wash‐out period for the use of PDE‐5i before the first LiSWT session (Chung 2022; Fojecki 2017; Harish 2017; Kalyvianakis 2017; Kim 2020; Kitrey 2016; Ortac 2021; Shendy 2021; Sramkova 2020; Srini 2015; Vardi 2012). One study had a washout period of eight weeks (Vinay 2021), two had a period of two weeks (Kennady 2023; Yee 2014), whereas one study set no washout period (Olsen 2015).

Eight studies used an LiSWT device with an electromagnetic energy source (Chung 2022; Kalyvianakis 2022; Kennady 2023; Kim 2020; Olsen 2015; Ortac 2021; Shendy 2021; Vinay 2021), six with an electrohydraulic energy source (Kalyvianakis 2017; Kitrey 2016; Spivak 2018; Srini 2015; Vardi 2012; Yee 2014), and three with a piezoelectric energy source (Fojecki 2017; Ong 2022; Sramkova 2020). Four studies did not report their treatment device or their energy source (Harish 2017; Vinay 2017; Xin 2017; Yang 2019).

Treatment frequency, number of shocks, energy density and frequency settings varied in each study and are demonstrated in the 'Overview of included studies' table (Table).

Outcomes

In the short term (≤ 3 months), 15 of 21 included studies reported the outcome of erectile function (Chung 2022; Fojecki 2017; Kalyvianakis 2017; Kalyvianakis 2022; Kennady 2023; Kim 2020; Kitrey 2016; Ong 2022; Ortac 2021; Shendy 2021; Sramkova 2020; Srini 2015; Vardi 2012; Vinay 2017; Vinay 2021). Seventeen of 21 studies reported on discontinuation from treatment (Chung 2022; Fojecki 2017; Kalyvianakis 2017; Kalyvianakis 2022; Kennady 2023; Kim 2020; Kitrey 2016; Olsen 2015; Ong 2022; Shendy 2021; Spivak 2018; Sramkova 2020; Vardi 2012; Vinay 2017; Vinay 2021; Yang 2019; Yee 2014). Twenty of 21 studies reported on treatment‐related adverse events (Chung 2022; Fojecki 2017; Harish 2017; Kalyvianakis 2017; Kalyvianakis 2022; Kennady 2023; Kim 2020; Kitrey 2016; Olsen 2015; Ong 2022; Ortac 2021; Shendy 2021; Spivak 2018; Sramkova 2020; Srini 2015; Vardi 2012; Vinay 2021; Xin 2017; Yang 2019; Yee 2014). Four of 21 studies reported the important outcome penile rigidity (Chung 2022; Kim 2020; Ong 2022; Sramkova 2020). We found no studies informing the outcomes patient/partner satisfaction and sexual quality of life.

For long‐term outcomes (> 3 months), five studies reported on erectile function (Chung 2022; Ong 2022; Ortac 2021; Srini 2015; Yee 2014). Six of 21 studies reported treatment‐related adverse events (Chung 2022; Fojecki 2017; Harish 2017; Kalyvianakis 2022; Ong 2022; Vinay 2021). Three of 21 studies informed penile rigidity (Chung 2022; Ong 2022; Yee 2014). No studies reported data on the critical outcome discontinuation from treatment, or the important outcomes patient/partner satisfaction and sexual quality of life.

Funding sources and conflicts of interest

Five studies reported that they had no funding (Fojecki 2017; Kennady 2023; Spivak 2018; Vinay 2017; Vinay 2021). Nine studies reported a funding source, usually from the device makers (Chung 2022; Kalyvianakis 2017; Kalyvianakis 2022; Kim 2020; Kitrey 2016; Olsen 2015; Ong 2022; Ortac 2021; Vardi 2012). The remaining studies provided no information on their funding sources (Harish 2017; Shendy 2021; Sramkova 2020; Srini 2015; Xin 2017; Yang 2019; Yee 2014).

Nine study authors reported no conflicts of interest (Chung 2022; Fojecki 2017; Kennady 2023; Kim 2020; Olsen 2015; Ong 2022; Ortac 2021; Sramkova 2020; Yee 2014). Five studies reported conflicts of interest with financial/other relationships to the device manufacturers (Kalyvianakis 2017; Kalyvianakis 2022; Kitrey 2016; Vardi 2012; Vinay 2021). The remaining studies provided no information on author conflicts of interest (Harish 2017; Shendy 2021; Spivak 2018; Srini 2015; Vinay 2017; Xin 2017; Yang 2019).

Excluded studies

We excluded nine records mapping seven studies in the full‐text literature screening stage. Details of exclusion reasons and references to these studies can be found in Supplementary material 3. Common reasons for exclusion were ineligible study design (non‐RCT) and ineligible patient population (e.g. post‐radical prostatectomy or in transplant patients). We also excluded one duplicate record.

Studies awaiting classification and ongoing studies

We listed one study as awaiting classification (Xin 2017a [91]). We found 14 ongoing studies. Additional details for these studies can be found in Supplementary material 4 and Supplementary material 5 respectively.

Risk of bias in included studies

Figure and Figure demonstrate our judgments on each risk of bias item for every included study and across all included studies. Most included studies did not report the method of allocation concealment and, therefore, we judged these at unclear risk of bias for selection bias. There were further issues with blinding in many studies that we deemed as either high or unclear risk. There was also unclear risk of bias for attrition bias in some of the outcomes. We found no other sources of bias.

Due to the above‐mentioned reasons, we consistently downgraded the certainty of evidence in our findings by one level for study limitations.

Synthesis of results

We have summarized these results in Table and Table. Details of our analyses are available in Supplementary material 6.

Short‐term outcomes

Critical outcomes
Erectile function

LiSWT, compared to sham treatment, may have a small effect on erectile function (MD 3.89 points higher, 95% CI 2.89 higher to 4.89 higher; I2 = 62%; 15 studies, 937 participants; low‐certainty evidence; Analysis 1.1; Figure). However, this small difference may not be clinically important as the assumed MCID was a 4‐point change in IIEF‐EF score (scale 6 to 30; higher score reflects higher erectile function).

4.

4

Forest plot for the outcome of erectile function short‐term.

We downgraded the certainty of evidence by two levels: one level for study limitations (unclear or high risk of bias in half or more domains) and one level for clinically important, serious inconsistency.

Discontinuation from treatment

LiSWT, compared to sham treatment, may have little to no effect on discontinuation from treatment (RR 0.77, 95% CI 0.47 to 1.27 higher; I2 = 0%; 17 studies, 1132 participants; low‐certainty evidence; Analysis 1.2; Figure). This corresponds to 15 fewer (34 fewer to 17 more) discontinuations from treatment with the use of LiSWT per 1000 patients. The MCID was assumed to be 5% absolute change.

5.

5

Forest plot for the outcome of discontinuation of treatment short‐term.

We downgraded the certainty of evidence by two levels: one level for study limitations (unclear or high risk of bias in half or more domains) and one level for clinically important, serious imprecision.

Treatment‐related adverse events

LiSWT, compared to sham treatment, may have little to no effect on treatment‐related adverse events (RD 0, 95% CI −0.01 to 0.02; I2 = 0%; 20 studies, 1400 participants; low‐certainty evidence; Analysis 1.3; Figure). The assumed MCID was a 5% absolute change.

6.

6

Forest plot for the outcome of treatment‐related adverse events short‐term.

We downgraded the certainty of evidence by two levels: one level for study limitations (unclear or high risk of bias in half or more domains) and one level for clinically important, serious imprecision.

Important outcomes
Patient/partner satisfaction

We found no evidence on patient/partner satisfaction.

Penile rigidity

LiSWT, compared to sham treatment, may improve penile rigidity (MD 1.06 points higher, 95% CI 0.83 higher to 1.28 higher; I2 = 53%; 4 studies, 252 participants; low‐certainty evidence; Analysis 1.4; Figure). The assumed MCID was a 1‐point change in EHS score (scale 1 to 4; higher score reflects higher penile rigidity).

7.

7

Forest plot for the outcome of penile rigidity short‐term.

We downgraded the certainty of evidence by two levels: one level for study limitations (unclear or high risk of bias in half or more domains) and one level for clinically important, serious imprecision.

Sexual quality of life

We found no evidence on sexual quality of life.

Subgroup analysis of critical outcomes (short term)

Subgroup analysis based on PDE‐5i response status

We grouped studies by their participants' response status to prior PDE‐5i therapy. We found the following effect sizes:

Erectile function
  • PDE‐5i responders: MD 0.1 points higher (95% CI −2.69 to 2.89; I2 = N/A; 1 study, 118 participants).

  • PDE‐5i non‐responders: MD 1.1 points higher (95% CI −1.52 to 3.72; I2 = N/A; 1 study, 47 participants).

The P value for the test of interaction indicated no evidence of a difference between subgroups (P = 0.61). Only two studies informed this subgroup analysis (Analysis 2.1).

Discontinuation from treatment
  • PDE‐5i responders: RR 1 (95% CI 0.15 to 6.88; I2 = N/A; 1 study, 126 participants).

  • PDE‐5i non‐responders: RR 0.35 (95% CI 0.10 to 1.19; I2 = N/A; 1 study, 58 participants).

The P value for the test of interaction indicated no evidence of a difference between subgroups (P = 0.37). Only two studies informed this subgroup analysis (Analysis 2.2).

Treatment‐related adverse events
  • PDE‐5i responders: RD 0 (95% CI −0.03 to 0.03; I2 = 0%; 2 studies, 183 participants).

  • PDE‐5i non‐responders: not estimable

The P value for the test of interaction was not applicable as we found no studies informing one of the subgroups (Analysis 2.3).

Sensitivity analysis of critical outcomes (short term)

We conducted a sensitivity analysis based on risk of bias by removing studies with a high risk of bias in any domain from the critical outcomes analyses.

Erectile function

Focusing on studies with low and unclear risk of bias only, we found an MD of 3.86 points higher (95% CI 2.79 to 4.93; I2 = 46%; 9 studies, 596 participants; Analysis 3.1).

Discontinuation from treatment

Focusing on studies with low and unclear risk of bias only, we found an RR of 0.91 (95% CI 0.53 to 1.56; I2 = 0%; 14 studies, 981 participants; Analysis 3.2).

Treatment‐related adverse events

Focusing on studies with low and unclear risk of bias only, we found an RD of 0 (95% CI ‐0.02 to 0.02; I2 = 0%; 14 studies, 971 participants; Analysis 3.3).

Long‐term outcomes

Critical outcomes
Erectile function

LiSWT, compared to sham treatment, may improve erectile function (MD 5.25 points higher, 95% CI 2.47 higher to 8.04 higher; I2 = 87%; 5 studies, 276 participants; low‐certainty evidence; Analysis 4.1). The assumed MCID was a 4‐point change in IIEF‐EF score (scale 6 to 30; higher score reflects higher erectile function).

We downgraded the certainty of evidence by two levels: one level for study limitations (unclear or high risk of bias in half or more domains) and one level for clinically important, serious inconsistency.

Discontinuation from treatment

There were no studies with an active treatment period longer than three months; therefore, we found no eligible data on this outcome.

Treatment‐related adverse events

LiSWT, compared to sham treatment, may have little to no effect on treatment‐related adverse events (RD 0, 95% CI −0.02 to 0.02; I2 = 0%; 6 studies, 411 participants; low‐certainty evidence; Analysis 4.2). The assumed MCID was a 5% absolute change.

We downgraded the certainty of evidence by two levels: one level for study limitations (unclear or high risk of bias in half or more domains) and one level for clinically important, serious imprecision.

Important outcomes
Patient/partner satisfaction

We found no evidence on patient/partner satisfaction.

Penile rigidity

LiSWT, compared to sham treatment, may have a small effect on penile rigidity (MD 0.91 points higher, 95% CI 0.36 higher to 1.46 higher; I2 = 89%; 3 studies, 169 participants; low‐certainty evidence; Analysis 4.3). However, this small effect may not be clinically important, as the assumed MCID was a 1‐point change in EHS score (scale 1 to 4; higher score reflects higher penile rigidity).

We downgraded the certainty of evidence by two levels: one level for study limitations (unclear or high risk of bias in half or more domains) and one level for clinically important, serious imprecision.

Sexual quality of life

We found no evidence on sexual quality of life.

Subgroup analysis of critical outcomes (long term)

Subgroup analysis based on PDE‐5i response status

We grouped studies by their participants' response status to prior PDE‐5i therapy. We found the following effect sizes:

Erectile function

We found no evidence informing this subgroup analysis.

Discontinuation from treatment

We found no evidence informing this subgroup analysis.

Treatment‐related adverse events
  • PDE‐5i responders: RD 0 (95% CI −0.03 to 0.03; I2 = 0%; 2 studies, 183 participants).

  • PDE‐5i non‐responders: not estimable

The test of interaction was not applicable as we found no studies informing one of the subgroups (Analysis 5.1).

Sensitivity analysis of critical outcomes (long term)

We conducted a sensitivity analysis based on risk of bias by removing studies with a high risk of bias in any domain from the critical outcomes analyses.

Erectile function

Focusing on studies with low and unclear risk of bias only, we found an MD of 4.27 points higher (95% CI 1.99 to 6.55; I2 = 69%; 3 studies, 169 participants; Analysis 6.1), which was similar to the results of the primary analysis.

Discontinuation from treatment

We found no evidence for this outcome.

Treatment‐related adverse events

Focusing on studies with low and unclear risk of bias only, we found an RD of 0 (95% CI −0.02 to 0.02; I2 = 0%; 6 studies, 411 participants; Analysis 6.2).

Reporting biases

We created funnel plots for the critical outcomes to assess publication bias in the included studies. Upon visual inspection, we found no asymmetry in the outcomes of erectile function and discontinuation from treatment. We found asymmetry in the treatment‐related adverse events outcome, but deemed this unlikely to be due to publication bias as the direction of asymmetry favors the sham treatment over intervention.

Discussion

Summary of main results

Based on our comprehensive review, LiSWT, compared to sham treatment, may have a small effect on erectile function that affected men may not perceive as clinically important in the short term. We also found that LiSWT may have no effect on discontinuation from treatment and treatment‐related adverse events in the short term. LiSWT may improve penile rigidity in the short term.

In the long term, LiSWT, compared to sham treatment, may improve erectile function. It may have little to no effect on treatment‐related adverse events. Penile rigidity may be improved, but once again the change may not be clinically important. There were no studies eligible for the outcome discontinuation from treatment, as none of the studies treated participants for longer than 12 weeks.

We deemed the certainty of the evidence for all our GRADE assessments as low, due to the below‐mentioned limitations in the evidence.

No studies reported data on patient/partner satisfaction and sexual quality of life outcomes, either in the short term or long term.

We found no evidence to suggest a subgroup effect based on PDE‐5i response or baseline severity in the included studies. Results of the sensitivity analyses based on risk of bias were similar to the primary analyses.

Limitations of the evidence included in the review

We downgraded the certainty of evidence for all outcomes consistently by two levels (low‐certainty evidence). Our reasons for downgrading the evidence are categorized below.

  • Study limitations: we consistently downgraded the certainty of evidence by one level for all the outcomes due to limitations in the included studies. Almost all included studies failed to describe the method of allocation concealment. More than half of the studies had issues with the blinding of study participants, personnel, and outcome assessors. There was a high risk of attrition bias in a number of studies. Only two studies were conducted according to a pre‐registered protocol (Kalyvianakis 2022; Kitrey 2016). Most studies did not provide details on a protocol, and one study had a registered protocol that the study authors deviated from and selectively reported their outcomes (Fojecki 2017).

  • Inconsistency: one common reason for downgrading the certainty of evidence was clinically relevant, serious inconsistency (corresponding to a high I2 value). Our predefined secondary analyses (subgroup and sensitivity analyses) failed to explain the observed heterogeneity. Aside from chance variation and methodological variety, clinical differences in each study participant profile (age, erectile dysfunction duration, baseline erectile dysfunction severity, erectile dysfunction etiology, etc.) are the potential source of these observed differences between individual study results.

  • Imprecision: the other common reason for downgrading the certainty of evidence was clinically important, serious imprecision. The decision to downgrade due to imprecision was made when the CIs around the point estimate crossed predefined MCID thresholds. In some instances, inconsistency appeared to be the underlying reason for the apparent imprecision. On such occasions, we did not downgrade further.

  • We were able to conduct the preplanned subgroup analyses based on PDE‐5i responses, but not based on baseline severity. Small sample sizes and low event rates limited our ability to demonstrate potential differences if they were to exist. Also, all comparisons were across, rather than within studies. Therefore, further subgroup analyses would risk identifying spurious subgroup effects through multiplicity. Meanwhile, our findings did not suggest any subgroup effects. The inability to better explore potential subgroup differences is a major limitation of this systematic review that is rooted in the available evidence, i.e. the lack of studies that provided preplanned stratified analyses based on important prognostic variables.

  • Only a few studies reported long‐term outcomes (Chung 2022; Ong 2022; Ortac 2021; Srini 2015; Yee 2014), and these were studies with more favorable short‐term results. This raises concerns around potential bias with longer‐term results being reported selectively by those studies with "positive" outcomes. The lack of protocols for most included studies prohibited us from investigating this issue further.

Although we did not formally investigate inequity in this review, we state the following potential areas of inequity that policymakers and providers must acknowledge and address to help ensure fair access to new therapies such as LiSWT.

  • Erectile dysfunction disproportionately affects certain demographics, such as older men and people with comorbidities. It is therefore important to ensure that LiSWT is accessible across various socioeconomic groups. This includes addressing potential barriers such as insurance coverage, which often dictates the availability and affordability of newer treatments. Additionally, there is a need for awareness and educational initiatives targeting both healthcare professionals and patients, emphasizing the availability and potential benefits of LiSWT, thereby preventing disparities in health literacy due to a lack of information.

  • As LiSWT remains a modality that is not covered by insurance, it therefore may result in inequities depending on coverage versus non‐coverage practices. The availability of this modality may not be uniform across different socioeconomic and geographical regions due to limitations in insurance coverage, which may be caused by the paucity of data in the literature that favors a positive treatment effect. This variety of availability might cause an economic barrier as the treatment may place significant out‐of‐pocket costs and disproportionately affect lower‐income men seeking treatment for erectile dysfunction. Additionally, there may be disparities in the availability of treatment devices in rural versus urban settings.

Limitations of the review processes

We conducted this Cochrane review according to a peer‐reviewed, published protocol [42]. This protocol included the description of a comprehensive literature search, predefined patient‐important outcomes, and established minimal clinically important thresholds. Nevertheless, we recognize the following as potential sources of bias.

  • Although we assessed publication bias by investigating funnel plots, we were only able to do so for our critical outcomes in the short term. Given the small number of studies, we were not able to assess publication bias with funnel plots for our long‐term outcomes.

  • We used a partially contextualized approach to investigate the results of this review beyond the concept of statistical significance by contemplating thresholds for MCIDs. Our MCIDs were informed by the literature and the clinical judgment of our content experts and were defined a priori. We recognize that choosing different thresholds would have affected the interpretation of the results. Specifically, Rosen and colleagues have proposed IIEF thresholds of 2, 5, and 7 for men with mild, moderate, and severe erectile dysfunction, respectively [49]. Since we expected most studies to include mixed populations of men with mild to moderate erectile dysfunction severity, we planned for an MCID of 4 as captured in our published protocol [42]. Since different assumptions about thresholds may result in different judgments about the effect sizes, we sought to make our judgments as transparent as possible to the readers.

Agreements and disagreements with other studies or reviews

We identified a number of systematic reviews on this topic, all with major methodological limitations.

  • A systematic review and meta‐analysis by Liu and colleagues on this topic included 11 RCTs [92]. The authors performed a limited search that also excluded articles that were not in English. Their search dated back to July 2020. The review did not have an a priori protocol, the risk of bias assessment was much more favorable than in this review, and the authors did not rate the certainty of evidence. Although the authors acknowledged the term MCID in their discussion, they failed to set thresholds for MCIDs and interpret their findings with regard to their clinical importance. They also included studies with kidney transplant population in their analysis, which we excluded as this represents a substantially different patient population. In contrast to our review, this study concluded with a much more favorable assessment of this treatment modality, stating that "compared with placebo treatment, Li‐ESWT alleviates ED [erectile dysfunction] symptoms in patients, particularly those who have mild or moderate ED". One reason for the differing interpretation is that the systematic review authors interpreted any statistically significant improvement as meaningful (for example, an increased IIEF‐EF score of 2.77 points [95% CI (1.74, 3.79)]), whereas we used predefined thresholds for what we would consider a clinically meaningful improvement.

  • Yao and colleagues did not report an a priori protocol, and did not assess the certainty of evidence [93]. The risk of bias assessments appeared overly favorable, and the interpretation of the results was focused on statistical significance rather than clinical importance. They also included transplant and prostatectomy patients, which we excluded. The results indicated that all men with erectile dysfunction may benefit from this treatment, but that the effect was most pronounced when an energy density of 0.09 mJ/mm2 and pulses numbers of 1500 to 2000 were used; also, the authors found that "IIEF improvement was more pronounced in patients with moderate ED". We would question the validity of these proposed subgroup effects based on the authors' methodology lacking the above‐mentioned measures, since none of these analyses were predefined by the systematic review authors nor did the trial authors plan these analyses. Instead, these analyses were based on across (rather than within) study comparisons. In addition, in neither case was the test for subgroup differences statistically significant. Based on the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) [94], the authors' interpretation is therefore questionable.

  • Lu and colleagues reported a systematic review with a search that dates back to November 2015 [22]. They did not report an apriori protocol and did not assess the certainty of evidence. The review also included populations that were even more different (Peyronie's disease, chronic pelvic pain syndrome, etc.) and pooled these different populations in the same meta‐analysis with the regular erectile dysfunction cohort, which we would question given this would increase indirectness. A sensitivity analysis focused on participants with erectile dysfunction only appears to have mistakenly included an RCT in men with chronic pelvic pain syndrome. This study also found that "LI‐ESWT could significantly improve IIEF" with an effect that "could last at least 3 months". Patients with mild‐moderate erectile dysfunction improved more than those with more severe erectile dysfunction. They further stated that "energy flux density, number of shock waves per treatment, and duration of LI‐ESWT treatment were closely related to clinical outcome, especially regarding IIEF improvement". Our protocol‐driven review could not verify these findings. We have concerns about the considerable clinical heterogeneity of the included trial participants, and about the overly optimistic interpretation of post hoc subgroup analyses. This study also did not consider any thresholds for clinically important differences, but interpreted any statistically significant improvements as clinically meaningful.

Authors' conclusions

Implications for practice

This Cochrane review constitutes the best current evidence explaining how low‐intensity shockwave therapy (LiSWT) compares to sham treatment for various patient‐important outcomes in treating erectile dysfunction. Overall, the pooled estimates suggest that LiSWT may have a small effect on erectile function in the short term, which affected men may not perceive as clinically important; erectile function may be improved in the long term. Penile rigidity may be improved in the short term; in the long term, the small change may not be clinically important. LiSWT may have little to no effect on treatment discontinuations in the short term, and on treatment‐related adverse events in both the short term and long term. We found no data on discontinuation from treatment in the long term, or on patient/partner satisfaction and sexual quality of life in the short term or long term.

We hope the findings of this Cochrane review aid decision‐making for men with erectile dysfunction who are considering treatment with LiSWT, providers who are contemplating the addition of LiSWT as an alternative option for treating erectile dysfunction, as well as policymakers.

Implications for research

Although the LiSWT technology for treating erectile dysfunction is a relatively recent development, there were many randomized controlled trials (RCTs) (in full‐text or abstract form) that met our inclusion criteria and informed our outcome analyses. This reflects the high interest in finding out whether LiSWT is effective and feasible in the erectile dysfunction population. We envision that this trend will likely continue and more studies informing the outcomes of this study will emerge. Based on the current evidence, we can state the following.

  • Similar to many other trials in urology [95, 96], RCTs evaluating LiSWT have several limitations in terms of methodology and quality of reporting. Main issues included the lack of transparent reporting of methods for randomization and allocation concealment, as well as the lack of a registered protocol. These underscore the importance of providing more training to current and future researchers in attempts to reach higher methodological quality and reporting standards.

  • Future research should prioritize inclusive study designs that encompass diverse participant demographics, reflecting the varied populations affected by erectile dysfunction. This includes considering factors such as age, race, socioeconomic status, and underlying health conditions. Such inclusivity in research will provide a more comprehensive understanding of the therapy’s effectiveness and safety across different groups.

  • The predefined secondary analysis in our Cochrane protocol did not suggest any meaningful subgroup effects that could explain some of the observed heterogeneity. Future trials should prospectively plan for an analysis that stratifies participants by important prognostic variables.

  • We came across numerous reported outcomes in this area of interest in many RCTs. These included a broad spectrum of outcomes, such as penile blood flow parameters, peak systolic velocity values, and resistive index, which may not be as important from a patient's perspective. It would be really helpful to the researchers in this field if there were an established set of patient‐important outcomes that are most relevant to decision‐making. We hope our Cochrane review also sets a baseline for these patient‐important outcomes that will be further investigated in the future by well‐done RCTs.

  • There is a need for studies focusing on the economic aspects of this treatment, such as cost‐effectiveness analyses and the impact of insurance coverage on patient access and adherence.

  • Research should also explore potential barriers to access and seek strategies to mitigate them.

Supporting Information

Supplementary materials are available with the online version of this article: 10.1002/14651858.CD013166.pub2.

Supplementary materials are published alongside the article and contain additional data and information that support or enhance the article. Supplementary materials may not be subject to the same editorial scrutiny as the content of the article and Cochrane has not copyedited, typeset or proofread these materials. The material in these sections has been supplied by the author(s) for publication under a Licence for Publication and the author(s) are solely responsible for the material. Cochrane accordingly gives no representations or warranties of any kind in relation to, and accepts no liability for any reliance on or use of, such material.

Supplementary material 1 Search strategies

Supplementary material 2 Characteristics of included studies

Supplementary material 3 Characteristics of excluded studies

Supplementary material 4 Characteristics of studies awaiting classification

Supplementary material 5 Characteristics of ongoing studies

Supplementary material 6 Analyses

Supplementary material 7 Data package

Supplementary material 8 Consumer Involvement

New

Additional information

Acknowledgements

Cochrane Urology supported the authors in the development of this intervention review.

Editorial and peer‐reviewer contributions

The following people conducted the editorial process for this article.

  • Sign‐off Editor (final editorial decision): Toby Lasserson, Cochrane Interim Editor‐in‐Chief;

  • Managing Editor (selected peer reviewers, provided editorial guidance to authors, edited the article): Ben Ridley, Central Editorial Service;

  • Editorial Assistant (conducted editorial policy checks, collated peer reviewers' comments and supported editorial team): Jacob Hester, Central Editorial Assistant;

  • Copy Editor (copy editing and production): Deirdre Walshe, Cochrane Central Production Service;

  • Peer reviewers (provided comments and recommended an editorial decision): Nikolaos Pyrgidis, Department of Urology, University Hospital, LMU Munich, Germany (clinical/content review); Paolo Capogrosso MD, University of Insubria ‐ ASST Sette Laghi, Varese, Italy (clinical/content review); Brian Duncan (consumer review); Nuala Livingstone, Cochrane Evidence Production and Methods Directorate (methods review); Anne Cleves Velindre University NHS Trust Library, Cardiff University (search review).

Contributions of authors

OE: wrote the protocol, screened studies, extracted data, assessed risk of bias, analyzed data, assessed the certainty of the evidence, and wrote the manuscript.

KK: revised and edited the protocol, screened studies, extracted data, assessed risk of bias, revised and edited the manuscript.

MHK: developed the search methods and provided methodological input.

ECH: revised the protocol, provided methodological input and arbitrated in the case of disagreements regarding GRADE ratings.

YB: revised the protocol, provided clinical input, revised and edited the manuscript.

AG: revised the protocol and manuscript, and provided clinical input.

SP: provided clinical input, provided consumer involvement source, and revised the manuscript.

PD: developed the review idea, revised the protocol; arbitrated in the case of disagreements regarding study selection, data extraction and risk of bias assessment; assessed the certainty of the evidence; revised and edited the manuscript; and administered the project.

Declarations of interest

OE was a Fellow of Cochrane Urology; however, he was not involved in the editorial process of this review.

KK declares no conflicts of interest.

MHK declares no conflicts of interest.

ECH is a Contact Editor for Cochrane Urology; however, he was not involved in the editorial process of this review.

YB declares no conflicts of interest.

AG declares no conflicts of interest.

SP declares no conflicts of interest.

PD is the Co‐ordinating Editor of Cochrane Urology; however, he was not involved in the editorial process of this review.

Sources of support

Internal sources

  • No source of support, Other

    None

External sources

  • No source of support, Other

    None

Registration and protocol

Protocol (2023) DOI: 10.1002/14651858.CD013166.pub2 [42].

Data, code and other materials

As part of the published Cochrane review, the following are made available for download for users of the Cochrane Library: full search strategies for each database (Supplementary material 1); full citations of each unique report for all studies included (Supplementary material 2), ongoing (Supplementary material 5), awaiting classification (Supplementary material 4), or excluded at the full‐text screen (Supplementary material 3), in the final review; study data, including study information, study arms, and study results or test data; consensus risk of bias assessments; and analysis data, including overall estimates and settings, subgroup estimates, and individual data rows (Supplementary material 6). Analyses and data management were conducted within Cochrane’s authoring tool, RevMan [65], using the inbuilt computation methods. Template data extraction forms in Excel format are available from the review authors on reasonable request.

History

Protocol first published: Issue 11, 2018

References

  • 1.Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, et al. Erectile dysfunction: AUA guideline. Journal of Urology 2018;200(3):633-41. [DOI] [PubMed] [Google Scholar]
  • 2.Allen MS, Walter EE. Erectile dysfunction: an umbrella review of meta-analyses of risk-factors, treatment, and prevalence outcomes. Journal of Sexual Medicine 2019;16(4):531-41. [DOI] [PubMed] [Google Scholar]
  • 3.McCabe MP, Sharlip ID, Lewis R, Atalla E, Balon R, Fisher AD, et al. Incidence and prevalence of sexual dysfunction in women and men: a consensus statement from the fourth international consultation on sexual medicine 2015. Journal of Sexual Medicine 2016;13(2):144-52. [DOI] [PubMed] [Google Scholar]
  • 4.Nguyen HM, Gabrielson AT, Hellstrom WJ. Erectile dysfunction in young men-a review of the prevalence and risk factors. Sexual Medicine Reviews 2017;5(4):508-20. [DOI] [PubMed] [Google Scholar]
  • 5.Yafi FA, Jenkins L, Albersen M, Corona G, Isidori AM, Goldfarb S, et al. Erectile dysfunction. Nature Reviews Disease Primers 2016;2:16003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Rasmussen S, Balasubramaniam K, Jarbøl DE, Søndergaard J, Haastrup PF. Socioeconomic status and barriers for contacting the general practitioner when bothered by erectile dysfunction: a population-based cross-sectional study. BMC Primary Care 2020;21(1):166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Cao S, Yin X, Wang Y, Zhou H, Song F, Lu Z. Smoking and risk of erectile dysfunction: systematic review of observational studies with meta-analysis. PLOS One 2013;8(4):e60443. [DOI: 10.1371/journal.pone.0060443] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lewis RW, Fugl-Meyer KS, Bosch R, Fugl-Meyer AR, Laumann EO, Lizza E, et al. Epidemiology/risk factors of sexual dysfunction. Journal of Sexual Medicine 2004;1(1):35-9. [DOI] [PubMed] [Google Scholar]
  • 9.Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, et al. European Association of Urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. European Urology 2021;80(3):333-57. [DOI] [PubMed] [Google Scholar]
  • 10.Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49(6):822-30. [DOI] [PubMed] [Google Scholar]
  • 11.Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. New England Journal of Medicine 1998;338(20):1397-404. [DOI] [PubMed] [Google Scholar]
  • 12.Ostfeld RJ, Allen KE, Aspry K, Brandt EJ, Spitz A, Liberman J, et al. Vasculogenic erectile dysfunction: the impact of diet and lifestyle. American Journal of Medicine 2021;134(3):310-6. [DOI] [PubMed] [Google Scholar]
  • 13.Hackett G, Krychman M, Baldwin D, Bennett N, El-Zawahry A, Graziottin A, et al. Coronary heart disease, diabetes, and sexuality in men. Journal of Sexual Medicine 2016;13(6):887-904. [DOI: 10.1016/j.jsxm.2016.01.023] [DOI] [PubMed] [Google Scholar]
  • 14.Shamloul R, Ghanem H. Erectile dysfunction. Lancet 2013;381(9861):153-65. [DOI] [PubMed] [Google Scholar]
  • 15.Melnik T, Soares B, Nasello AG. Psychosocial interventions for erectile dysfunction. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No: CD004825. [DOI: 10.1002/14651858.CD004825.pub2] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Yuan JQ, Zhang RJ, Yang ZY, Lee J, Liu YL, Tian JH, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. European Urology 2013;63(5):902-12. [DOI] [PubMed] [Google Scholar]
  • 17.Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003;61(4):8-14. [DOI] [PubMed] [Google Scholar]
  • 18.Irwin GM. Erectile dysfunction. Journal of Primary Care & Community Health 2019;46(2):249-55. [DOI] [PubMed] [Google Scholar]
  • 19.Mobley DF, Khera M, Baum N. Recent advances in the treatment of erectile dysfunction. Postgraduate Medical Journal 2017;93(1105):679-85. [DOI] [PubMed] [Google Scholar]
  • 20.Philippou YA, Jung JH, Steggall MJ, O'Driscoll ST, Bakker CJ, Bodie JA, et al. Penile rehabilitation for postprostatectomy erectile dysfunction. Cochrane Database of Systematic Reviews 2018, Issue 10. Art. No: CD012414. [DOI: 10.1002/14651858.CD012414.pub2] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Lee HW, Lee MS, Kim T-H, Alraek T, Zaslawski C, Kim JW, et al. Ginseng for erectile dysfunction. Cochrane Database of Systematic Reviews 2021, Issue 4. Art. No: CD012654. [DOI: 10.1002/14651858.CD012654.pub2] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Lu Z, Lin G, Reed-Maldonado A, Wang C, Lee Y-C, Lue TF. Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. European Urology 2017;71(2):223-33. [DOI] [PubMed] [Google Scholar]
  • 23.Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. European Urology 2010;58(2):243-8. [DOI] [PubMed] [Google Scholar]
  • 24.Canguven O, Khalafalla K, Al Ansari A. Low-intensity extracorporeal shockwave therapy for erectile dysfunction. Arab Journal of Urology 2021;19(3):340-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bakr AM, El-Sakka AI. Extracorporeal shockwave therapy in Peyronie's disease: systematic review and meta-analysis. Journal of Sexual Medicine 2021;18(10):1705-14. [DOI] [PubMed] [Google Scholar]
  • 26.Campbell JD, Matti D, Abed H, Di Pierdominico A. Technological advancements for treating erectile dysfunction and Peyronie's disease. Medical Clinics of North America 2022;49(1):175-84. [DOI] [PubMed] [Google Scholar]
  • 27.Clavijo RI, Kohn TP, Kohn JR, Ramasamy R. Effects of low-intensity extracorporeal shockwave therapy on erectile dysfunction: a systematic review and meta-analysis. Journal of Sexual Medicine 2017;14(1):27-35. [DOI] [PubMed] [Google Scholar]
  • 28.Lohrer H, Nauck T, Dorn-Lange NV, Schöll J, Vester JC. Comparison of radial versus focused extracorporeal shock waves in plantar fasciitis using functional measures. Foot & Ankle International 2010;31(1):1-9. [DOI] [PubMed] [Google Scholar]
  • 29.Katz JE, Clavijo RI, Rizk P, Ramasamy R. The basic physics of waves, soundwaves, and shockwaves for erectile dysfunction. Sexual Medicine Reviews 2020;8(1):100-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Sighinolfi MC, Eissa A, Bellorofonte C, Mofferdin A, Eldeeb M, Assumma S, et al. Low-intensity extracorporeal shockwave therapy for the management of postprostatectomy erectile dysfunction: a systematic review of the literature. European Urology Open Science 2022;30:45-53. [DOI: 10.1016/j.euros.2022.07.003] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Kurosawa M, Tsujimura A, Morino J, Anno Y, Yoshiyama A, Kure A, et al. Efficacy and patient satisfaction of low-intensity shockwave treatment for erectile dysfunction in a retrospective real-world study in Japan. International Journal of Urology 2023;30(4):375-80. [DOI: 10.1111/iju.15135] [DOI] [PubMed] [Google Scholar]
  • 32.Sandoval-Salinas C, Saffon JP, Corredor HA, Fonseca L, Manrique L, Solis G. Are radial pressure waves effective in treating erectile dysfunction? A systematic review of preclinical and clinical studies. Journal of Sexual Medicine 2021;9(4):100393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Patel P, Katz J, Lokeshwar SD, Molina M, Reis IM, Clavijo R, et al. Phase II randomized, clinical trial evaluating 2 schedules of low-intensity shockwave therapy for the treatment of erectile dysfunction. Journal of Sexual Medicine 2020;8(2):214-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Reisman Y, Hind A, Varaneckas A, Motil I. Initial experience with linear focused shockwave treatment for erectile dysfunction: a 6-month follow-up pilot study. International Journal of Impotence Research 2015;27(3):108-12. [DOI] [PubMed] [Google Scholar]
  • 35.Gruenwald I, Appel B, Kitrey ND, Vardi Y. Shockwave treatment of erectile dysfunction. Therapeutic Advances in Urology 2013;5(2):95-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Yuan F, Wang Y, Ma Z, Jing M, You Y, Yu X, et al. Low-intensity extracorporeal shockwave therapy for erectile dysfunction: an overview of systematic reviews. Translational Andrology and Urology 2021;10(9):3684-96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Young Academic Urologists Men's Health Group; Fode M, Hatzichristodoulou G, Serefoglu EC, Verze P, Albersen M. Low-intensity shockwave therapy for erectile dysfunction: is the evidence strong enough? Nature Reviews Urology 2017;14(10):593-606. [DOI] [PubMed] [Google Scholar]
  • 38.Nurzynska D, Di Meglio F, Castaldo C, Arcucci A, Marlinghaus E, Russo S, et al. Shock waves activate in vitro cultured progenitors and precursors of cardiac cell lineages from the human heart. Ultrasound in Medicine & Biology 2008;34(2):334-42. [DOI] [PubMed] [Google Scholar]
  • 39.Peng D, Tan Y, Reed-Maldonado AB, Lin G, Lue TF. Molecular mechanism of action of low-intensity extracorporeal shockwave therapy for regenerating penile and peripheral nerves. Turkish Journal of Urology 2020 Oct 9 [Epub ahead of print]. [DOI: 10.5152/tud.2020.20419] [DOI] [PubMed]
  • 40.Usta MF, Gabrielson AT, Bivalacqua TJ. Low-intensity extracorporeal shockwave therapy in the treatment of erectile dysfunction following radical prostatectomy: a critical review. International Journal of Impotence Research 2019;31(3):231-8. [DOI] [PubMed] [Google Scholar]
  • 41.Zou Z-J, Tang L-Y, Liu Z-H, Liang J-Y, Zhang R-C, Wang Y-J, et al. Short-term efficacy and safety of low-intensity extracorporeal shock wave therapy in erectile dysfunction: a systematic review and meta-analysis. International Brazilian Journal of Urology 2017;43:805-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ergun O, Kim K, Kim MH, Hwang EC, Blair Y, Gudeloglu A, et al. Low-intensity shockwave therapy for erectile dysfunction. Cochrane Database of Systematic Reviews 2023, Issue 9. Art. No: CD013166. [DOI: 10.1002/14651858.CD013166.pub2] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Higgins JP, Lasserson T, Thomas J, Flemyng E, Churchill R. Methodological Expectations of Cochrane Intervention Reviews (MECIR). Version August 2023. Cochrane, London. Available at community.cochrane.org/mecir-manual.
  • 44.Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. [DOI: 10.1136/bmj.n71] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Higgins JP, Eldridge S, Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023. Available from training.cochrane.org/handbook.
  • 46.Wu SS, Ericson KJ, Shoskes DA. Retrospective comparison of focused shockwave therapy and radial wave therapy for men with erectile dysfunction. Translational Andrology and Urology 2020;9(5):2122-8. [DOI: 10.21037/tau-20-911] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Rhoden EL, Telöken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. International Journal of Impotence Research 2002;14(4):245-50. [DOI] [PubMed] [Google Scholar]
  • 48.Rosenberg JE, Ergun O, Hwang EC, Risk MC, Jung JH, Edwards ME, et al. Non-surgical therapies for Peyronie's disease. Cochrane Database of Systematic Reviews 2023, Issue 7. Art. No: CD012206. [DOI: 10.1002/14651858.CD012206.pub2] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. European Urology 2011;60(5):1010-6. [DOI] [PubMed] [Google Scholar]
  • 50.Watts RJ. Sexual functioning, health beliefs, and compliance with high blood pressure medications. Nursing Research 1982;31(5):278-83. [PubMed] [Google Scholar]
  • 51.Watt JA, Veroniki AA, Tricco AC, Straus SE. Using a distribution-based approach and systematic review methods to derive minimum clinically important differences. BMC Medical Research Methodology 2021;21:41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Alappattu M, Harrington SE, Hill A, Roscow A, Jeffrey A. Oncology Section EDGE Task Force on Cancer: a systematic review of patient-reported measures for sexual dysfunction. Rehabilitation Oncology 2017;35(3):137-43. [PMC free article] [PubMed] [Google Scholar]
  • 53.Abraham L, Symonds T, Morris MF. Psychometric validation of a sexual quality of life questionnaire for use in men with premature ejaculation or erectile dysfunction. Journal of Sexual Medicine 2008;5(3):595-601. [DOI] [PubMed] [Google Scholar]
  • 54.EndNote. Version 20. Philadelphia (PA): Clarivate, 2022. Available from www.endnote.com.
  • 55.Covidence. Version accessed 11 January 2023. Melbourne, Australia: Veritas Health Innovation, 2024. Available at www.covidence.org.
  • 56.Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.
  • 57.Chung E, Bailey W, Wang J. A prospective, randomized, double-blinded, clinical trial using a second-generation duolith SD1 low-intensity shockwave machine in males with vascular erectile dysfunction. World Journal of Men's Health 2022;41(1):94-100. [DOI: 10.5534/wjmh.210123] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Fojecki GL, Tiessen S, Osther PJ. Effect of low-energy linear shockwave therapy on erectile dysfunction-a double-blinded, sham-controlled, randomized clinical trial. Journal of Sexual Medicine 2017;14(1):106-12. [DOI: 10.1016/j.jsxm.2016.11.307] [DOI] [PubMed] [Google Scholar]
  • 59.Harish-Kumar G, Ravichandran R, Venugopal K. Low intensity extracorporeal shockwave therapy for erectile dysfunction: our experience. Indian Journal of Urology 2017;33(Suppl 1):S43–S178. [PMID: ] [Google Scholar]
  • 60.Higgins JP, Altman DG, Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from cochrane-handbook.org.
  • 61.Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.
  • 62.Kennady EH, Bryk DJ, Ali MM, Ratcliffe SJ, Mallawaarachchi IV, Ostad BJ, et al. Low-intensity shockwave therapy improves baseline erectile function: a randomized sham-controlled crossover trial. Sexual Medicine 2023;11(5):qfad053. [DOI: 10.1093/sexmed/qfad053] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. Journal of Urology 2012;187(5):1769-75. [DOI: 10.1016/j.juro.2011.12.117] [DOI] [PubMed] [Google Scholar]
  • 64.Vinay J, Moreno D, Vives A, Rajmil O, Ruiz-Castane E, Sanchez-Curbelo J. Electrohydraulic low-intensity shockwave therapy for PDE5i-refractory erectile dysfunction: a prospective, randomized, placebo-controlled study. Journal of Urology 2017;197(4S):E1218. [DOI: 10.1016/j.juro.2017.02.2841] [DOI] [Google Scholar]
  • 65.Review Manager (RevMan). Version 9.1.0. The Cochrane Collaboration, 2025. Available at revman.cochrane.org.
  • 66.Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58. [DOI: 10.1002/sim.1186] [DOI] [PubMed] [Google Scholar]
  • 67.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.
  • 69.Tzou K-Y, Hu S-W, Adebayo Bamodu O, Wang Y-H, Wu W-L, Wu C-C. Efficacy of penile low-intensity shockwave therapy and determinants of treatment response in Taiwanese patients with erectile dysfunction. Biomedicines 2021;9(11):1670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Schünemann HJ, et al. GRADE: what is "quality of evidence" and why is it important to clinicians? BMJ 2008;336(7651):995-8. [DOI: 10.1136/bmj.39490.551019.BE] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.GRADEpro GDT. Version accessed 11 January 2023. Hamilton (ON): McMaster University (developed by Evidence Prime), 2023. Available at gradepro.org.
  • 72.Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [DOI: 10.1016/j.jclinepi.2010.04.026] [DOI] [PubMed] [Google Scholar]
  • 73.Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023. Available from training.cochrane.org/handbook.
  • 74.Zeng L, Brignardello-Petersen R, Hultcrantz M, Mustafa RA, Murad MH, Iorio A, et al. GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. Journal of Clinical Epidemiology 2022;150:216-24. [DOI] [PubMed] [Google Scholar]
  • 75.Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology 2020;119:126-35. [DOI] [PubMed] [Google Scholar]
  • 76.Kalyvianakis D, Hatzichristou D. Low-intensity shockwave therapy improves hemodynamic parameters in patients with vasculogenic erectile dysfunction: a triplex ultrasonography-based sham-controlled trial. Journal of Sexual Medicine 2017;14(7):891-7. [DOI: 10.1016/j.jsxm.2017.05.012] [DOI] [PubMed] [Google Scholar]
  • 77.Kalyvianakis D, Mykoniatis I, Pyrgidis N, Kapoteli P, Zilotis F, Fournaraki A, et al. The effect of low-intensity shock wave therapy on moderate erectile dysfunction: a double-blind, randomized, sham-controlled clinical trial. Journal of Urology 2022;208(2):388-95. [DOI: 10.1097/JU.0000000000002684] [DOI] [PubMed] [Google Scholar]
  • 78.Kim KS, Jeong HC, Choi SW, Choi YS, Cho HJ, Ha US, et al. Electromagnetic low-intensity extracorporeal shock wave therapy in patients with erectile dysfunction: a sham-controlled, double-blind, randomized prospective study. World Journal of Men's Health 2020;38(2):236-42. [DOI: 10.5534/wjmh.190130] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Kitrey ND, Gruenwald I, Appel B, Shechter A, Massarwa O, Vardi Y. Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: a double-blind, sham controlled study. Journal of Urology 2016;195(5):1550-5. [DOI: 10.1016/j.juro.2015.12.049] [DOI] [PubMed] [Google Scholar]
  • 80.Olsen AB, Persiani M, Boie S, Hanna M, Lund L. Can low-intensity extracorporeal shockwave therapy improve erectile dysfunction? A prospective, randomized, double-blind, placebo-controlled study. Scandinavian Journal of Urology 2015;49(4):329-33. [DOI: 10.3109/21681805.2014.984326] [DOI] [PubMed] [Google Scholar]
  • 81.Ong WL, Lechmiannandan S, Lim YL, Manoharan D, Lee SB. Early outcomes of short-course low intensity shockwave therapy (LiSWT) for erectile dysfunction: a prospective, randomized, double-blinded, sham-controlled study in Malaysia. Andrologia 2022;54(9):e14518. [DOI: 10.1111/and.14518] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Ortac M, Ozmez A, Cilesiz NC, Demirelli E, Kadioglu A. The impact of extracorporeal shock wave therapy for the treatment of young patients with vasculogenic mild erectile dysfunction: a prospective randomized single-blind, sham controlled study. Andrology 2021;9(5):1571-8. [DOI: 10.1111/andr.13007] [DOI] [PubMed] [Google Scholar]
  • 83.Shendy WS, Elsoghier OM, El Semary MM, Ahmed AA, Ali AF, Saber-Khalaf M. Effect of low-intensity extracorporeal shock wave therapy on diabetic erectile dysfunction: randomised control trial. Andrologia 2021;53(4):e13997. [DOI: 10.1111/and.13997] [DOI] [PubMed] [Google Scholar]
  • 84.Sramkova T, Motil I, Jarkovsky J, Sramkova K. Erectile dysfunction treatment using focused linear low-intensity extracorporeal shockwaves: single-blind, sham-controlled, randomized clinical trial. Urologia Internationalis 2020;104(5-6):417-24. [DOI: 10.1159/000504788] [DOI] [PubMed] [Google Scholar]
  • 85.Srini VS, Reddy RK, Shultz T, Denes B. Low intensity extracorporeal shockwave therapy for erectile dysfunction: a study in an Indian population. Canadian Journal of Urology 2015;22(1):7614-22. [PMID: ] [PubMed] [Google Scholar]
  • 86.Vinay J, Moreno D, Rajmil O, Ruiz-Castane E, Sanchez-Curbelo J. Penile low intensity shock wave treatment for PDE5I refractory erectile dysfunction: a randomized double-blind sham-controlled clinical trial. World Journal of Urology 2021;39(6):2217-22. [DOI: 10.1007/s00345-020-03373-y] [DOI] [PubMed] [Google Scholar]
  • 87.Yee C-H, Chan ES, Hou SS-M, Ng C-F. Extracorporeal shockwave therapy in the treatment of erectile dysfunction: a prospective, randomized, double-blinded, placebo controlled study. International Journal of Urology 2014;21(10):1041-5. [DOI: 10.1111/iju.12506] [DOI] [PubMed] [Google Scholar]
  • 88.Spivak L, Vinarov A, Platonova D, Demidko Y. Extracorporeal shock-wave therapy (ESWT) in treatment of ED: results of sham-controlled study. Journal of Urology 2018;199(4):e1175. [DOI: 10.1016/j.juro.2018.02.2876] [DOI] [Google Scholar]
  • 89.Xin ZC, Guan RL, Cui WS, Zhang XD, Tian L, Xie Y, et al. Safety and efficacy of low-intensity extracorporeal shockwave in the treatment of vasculogenic erectile dysfunction: a multicenter, double-blind, randomized sham-controlled clinical trial. Journal of Urology 2017;197(4):E1345-6. [DOI: 10.1016/j.juro.2017.02.3145] [DOI] [Google Scholar]
  • 90.Yang L, Chen X, He D. Linear focus low-intensity extracorporeal shockwave therapy in the treatment of erectile dysfunction: a multi-center, double-blinded, prospective, randomized, placebo-controlled study. European Urology Supplements 2019;18(1):e1624. [DOI: 10.1016/S1569-9056(19)31176-5] [DOI] [Google Scholar]
  • 91.ChiCTR1800020212. Efficacy and safety of E100 shock wave therapy sytem for the treatment of mild to moderate erectile dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR1800020212 (first posted 20 December 2018).
  • 92.Liu S, Pu J, Li X, Li R, Wang Y, Dong Z. Effects of low-intensity extracorporeal shockwave therapy on erectile dysfunction: a systematic review and meta-analysis. Journal of the College of Physicians and Surgeons Pakistan 2022;32(9):1181-6. [DOI: 10.29271/jcpsp.2022.09.1181] [DOI] [PubMed] [Google Scholar]
  • 93.Yao H, Wang X, Liu H, Sun F, Tang G, Bao X, et al. Systematic review and meta-analysis of 16 randomized controlled trials of clinical outcomes of low-intensity extracorporeal shock wave therapy in treating erectile dysfunction. American Journal of Men's Health 2022;16(2):15579883221087532. [DOI: 10.1177/15579883221087532] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA, et al. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ: Canadian Medical Association Journal 2020;192(32):E901-6. [DOI: 10.1503/cmaj.200077] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Thompson E, Lai A, Morrey L, Borofsky MS, Dahm P. A longitudinal assessment of the reporting quality of randomized controlled trials for surgical interventions to treat nephrolithiasis over 16 ears (2002 to 2017). Journal of Endourology 2020;34(4):502-8. [DOI: 10.1089/end.2019.0649] [DOI] [PubMed] [Google Scholar]
  • 96.Zavitsanos PJ, Bird VG, Mince KA, Neuberger MM, Dahm P. Low methodological and reporting quality of randomized, controlled trials of devices to treat urolithiasis. Journal of Urology 2014;191(4):988-93. [DOI: 10.1016/j.juro.2013.10.067] [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary material 1 Search strategies

Supplementary material 2 Characteristics of included studies

Supplementary material 3 Characteristics of excluded studies

Supplementary material 4 Characteristics of studies awaiting classification

Supplementary material 5 Characteristics of ongoing studies

Supplementary material 6 Analyses

Supplementary material 7 Data package

Supplementary material 8 Consumer Involvement

Data Availability Statement

As part of the published Cochrane review, the following are made available for download for users of the Cochrane Library: full search strategies for each database (Supplementary material 1); full citations of each unique report for all studies included (Supplementary material 2), ongoing (Supplementary material 5), awaiting classification (Supplementary material 4), or excluded at the full‐text screen (Supplementary material 3), in the final review; study data, including study information, study arms, and study results or test data; consensus risk of bias assessments; and analysis data, including overall estimates and settings, subgroup estimates, and individual data rows (Supplementary material 6). Analyses and data management were conducted within Cochrane’s authoring tool, RevMan [65], using the inbuilt computation methods. Template data extraction forms in Excel format are available from the review authors on reasonable request.


Articles from The Cochrane Database of Systematic Reviews are provided here courtesy of Wiley

RESOURCES